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Abstract 
 
Enteral nutrition (EN) or enteral tube feeding is an effective means of nutritional support 
for individuals who do not or cannot eat adequately.  Patients restricted to EN frequently 
suffer from abnormal bowel function which affects their intestinal bacteria and impacts 
quality of life.  Dietary fibers have a variety of physiological benefits; fibers that provide 
fecal bulk promote regular bowel movements while fermentable fibers are utilized by gut 
bacteria to produce short chain fatty acids (SCFA) and gas in the process.  SCFAs 
positively influence gut health, gut transit time, and fecal moisture while gas may reduce 
the tolerance of fibers.  Fortification of EN with a blend of fibers with various 
physicochemical properties more closely represents a normal diet, and may maximize 
physiological benefits.  Moreover, using a blend of fibers with different rates of 
fermentation may minimize gas and bloating commonly associated with highly 
fermentable fibers.    
 
Batch in vitro systems allow fiber fermentation modeling without absorption and may 
help to estimate potential health benefits and gastrointestinal tolerance of fiber in vivo.  
Well controlled, blinded and randomized intervention human studies are the “gold 
standard” for human nutrition research.  The primary aim of this project was to conduct a 
human clinical trial utilizing a fiber blend fortified EN product.  The secondary aim was 
to relate the human study findings to the in vitro fermentation profiles of the fiber blend 
and its individual components.   
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The objective of the human study was to compare the effects of a fiber blend fortified 
enteral formula (FB, 15 g/L), a fiber-free formula (FF) and habitual diet on bowel 
function, fecal bacteria and quality of life.  The fiber blend consisted of a 50:50 
insoluble:soluble ratio of fructo-oligosaccharides (FOS), inulin, gum acacia and outer pea 
hull fiber.  In a randomized, double-blind, crossover design, 20 healthy subjects 
consumed both FF and FB for 14 days with a 4 week washout.  Fecal samples were 
collected the last 5 days of each period and assessed for fecal output, whole gut transit 
time (WGTT), and major bacterial groups.  Subject gastrointestinal quality of life index 
(GIQLI) and tolerance were also measured.  On formula diets, 5-day fecal output 
decreased by more than 55% from habitual diet, but was 38% higher on FB than FF 
(p=0.0321).  WGTT was approximately 1.5 times longer on formula diets than habitual 
diet (p<0.0004). Total bacteria declined from habitual diet on FF (p<0.004), but not on 
FB.  Numbers of bifidobacteria and lactobacilli declined from habitual diet on both 
formula diets, but bifidobacteria was higher on FB compared to FF (p<0.0001).  
Bacteroides and clostridia numbers did not change between diets.   GIQLI and incidence 
of gas symptoms did not differ between formulas.  
 
The objectives of the second project were to compare the in vitro fermentation profiles of 
FOS, inulin, gum acacia, and pea fiber alone or blended using a 24 h batch model and 
relate these finding to the human study results.  For the in vivo measurements, stool 
samples were collected to measure pH and SCFA.  Tolerance was also measured.  The in 
vitro fermentation of the fiber blend resulted in a delayed pH decrease and gas and SCFA 
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production compared to the FOS and inulin.  Human samples had higher total SCFA on 
the fiber formula compared to the fiber free formula (p=0.029), and both formulas 
yielded lower SCFA than habitual diet (both p<0.0001). Mean fecal pH for both formulas 
was 7.5; higher than habitual diet pH 6.5 (p<0.0001).  No differences in gas/bloating 
were found between any diet.    By blending fibers, a slower fermentation was observed 
in vitro and was well tolerated in human subjects.  Fiber addition to enteral formula 
increases fecal short chain fatty acids which may reflect increased fermentation.   
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CHAPTER ONE 
Literature Review 
Definition of dietary fiber 
Determining a single definition of the diverse compounds considered to be “fiber” has 
been a debate since the early 1950s (1) and still differs among organizations.  The 
American Association of Cereal Chemists defines dietary fiber as “the edible parts of 
plants or analogous carbohydrates that are resistant to digestion and absorption in the 
human small intestine with complete or partial fermentation in the large intestine.  
Dietary fiber includes polysaccharides, oligosaccharides, lignin, and associated plant 
substances.  Dietary fibers promote beneficial physiological effects including laxation, 
and/or blood cholesterol attenuation, and/or blood glucose attenuation” (2).  Of clinical 
relevance, the Food and Nutrition Board of the Institute of Medicine proposed that fiber 
be split into categories: dietary fiber is the non-digestible carbohydrates and lignin 
occurring intrinsically and intact in plants; functional fiber is the isolated, non-digestible 
carbohydrates which exert beneficial physiological effects in humans; and total fiber is 
the sum of dietary and functional fiber (3).  Most recently, the Codex Alimentarius 
Commission of the United Nations Food and Agriculture Organization/World Health 
Organization Food Standards Program, attempted to standardize the use of the term and 
proposed that “dietary fibre means carbohydrate polymers with ten or more monomeric 
units, which are not hydrolysed by the endogenous enzymes in the small intestine of 
humans and belong to the following categories: 1) edible carbohydrate polymers 
naturally occurring in the food as consumed; 2) carbohydrate polymers, which have been 
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obtained from food raw material by physical, enzymatic or chemical means and which 
have been shown to have a physiological effect of benefit to heath as demonstrated by 
generally accepted scientific evidence to competent authorities; 3) synthetic carbohydrate 
polymers which have been shown to have a physiological effect of benefit to health as 
demonstrated by generally accepted scientific evidence to competent authorities”(4).  The 
definition further states “when from a plant origin, dietary fibre may include fractions of 
lignin and/or other compounds associated with polysaccharides in the plant cell walls and 
that the decision on whether to include carbohydrates from 3-9 monomeric units should 
be left to national authorities” (4). 
 
In the United States, the Nutrition Facts panel on food labels report amounts of fiber as 
determined/defined by chemical methods approved by the Association of Analytical 
Chemists (AOAC) (5).  Methods exist for determining total fiber, insoluble fiber, and 
soluble fiber although due to the diversity of compounds defined as fiber, additional 
methods are being used and developed to quantify specific components (e.g. inulin).   
The amount of total fiber must be included on the food label while amounts of insoluble 
and soluble fiber are voluntary unless a specific health claim relating to fiber is made.  
Classification of fiber solubility is based on its ability to dissolve in aqueous solutions 
(6).   
 
Physicochemical properties of fiber  
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By definition, fibers are non-digestible to the human but include a wide range of 
compounds with various physicochemical properties.  The chemical composition and 
physical structure of fiber largely dictates the physiological effects of in the body.  The 
most important properties of fiber believed to influence its physiological and nutritional 
effects include solubility and hydration properties, viscosity, and fermentability (7).   
 
The carbohydrate constituents (chemical composition), chain length and degree of 
carbohydrate branching (physical structure) of a fiber influences its solubility.  For 
example, linear polymers of β (1,4) linked glucose (cellulose) that are packed together 
into an ordered assembly may resist hydration and neither absorb water or dissolve (8). 
Other neutral polymers may be able to swell and absorb some water (water binding 
capacity) while others such as fructose polymers may be able to totally dissolve and exist 
in solution.  Other fibers such as pectin may be ionic and pH/ionic environment of the gut 
would influence solubility (9).  The integrity of the cell wall in a fiber particulate may 
also influence solubility and water binding capacity.  Extensive packing of 
polysaccharide chains into ordered structures in cell walls may be further stabilized by 
lignifications and resist hydration (10).   
 
Viscosity, or the measure of resistance to flow, is influenced by the fiber’s 
physicochemical properties in addition to the concentration of fiber in the gastrointestinal 
tract (10).  Polymeric fibers able to dissolve and entangle increase the viscosity of the gut 
contents, with longer chain polymers creating higher viscosities (9).  Insoluble fibers may 
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also contribute to viscosity as particulates increase viscosity, but because of the compact 
physical form, make a smaller contribution to digesta viscosity than dissolved 
polysaccharides (10).  
 
Fermentation is the incomplete oxidation of substances in the absence of oxygen, and 
fiber fermentability refers to the ability of the gut bacteria to breakdown and metabolize 
fiber (11).  Soluble fibers are more accessible to gut microbe enzymes due to their ability 
to swell and/or dissolve which influences fermentability (10).  Since the fermentation of 
insoluble fibers may be limited, the physiological effects are more related to the fiber’s 
physical properties of water holding capacity and fecal bulking (12).     
 
 
Prebiotic fibers- definition, requirements and index 
 
In 1995, the term prebiotics was introduced as a “non-digestible food ingredient that 
beneficially affects the host by selectively stimulating the growth and/or activity of one 
or a limited number of bacterial species already resident in the colon, and thus attempts to 
improve host health” (13).   By 2004, a refined definition was published.  The updated 
definition stated that “a prebiotic is a selectively fermented ingredient that allows specific 
changes, both in the composition and/or activity in the gastrointestinal microflora, that 
confers benefits upon host well-being and health” (14).   Classification of a food 
component as a prebiotic was contingent upon meeting these criteria; “1) non-digestible 
i.e. resistant to gastric acidity, and hydrolysis by mammalian enzymes and 
gastrointestinal absorption,  2) fermentation by intestinal microflora,  3) selective 
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stimulation of the growth and/or activity of intestinal bacterial associated with health and 
well-being” (14).  This definition is generally used in literature and is referenced in a 
number of reviews, book chapters and proceedings (15-20).  By definition, prebiotics are 
dietary fibers, but not all dietary fibers are prebiotic. 
 
To be considered a prebiotic, a food component must be non-digestible, fermented by the 
intestinal microflora, and selectively stimulate the growth and/or activity of the intestinal 
bacteria associated with host health.  Ideally, potential prebiotics would be tested to fulfill 
each criterion using protocols that are validated to measure and/or model in vivo 
conditions (14).  To determine digestibility, substances must be resistant to endogenous 
gastric acid and enzymatic digestion, and although complete resistance to human 
digestion is not necessary, a “significant amount” should be available for fermentation 
(21) .  Fermentation by the intestinal microflora is commonly measured using in vitro 
systems that utilize fecal slurries or rats that have been inoculated with human fecal floral 
although fermentation can also be indirectly measured via breath hydrogen or fecal 
recovery (22, 23).  Measuring selective growth and activity is the most complex; the 
beneficial species must be known and distinguishable from other bacteria and current 
estimates approximate the human gut microbiome to include over 400-800 cultivatable 
and non-cultivatable species (17).  Although which bacteria are beneficial and pathogenic 
is not currently agreed upon or known in entirety, certain traits show promise.  Beneficial 
or health-promoting effects of microbes include the inhibition of growth of harmful 
bacteria (nutrient/site competition or antimicrobial production), improved digestion of 
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nutrients, decreased gas, improved bowel function, absence of toxin production, 
immunity benefits and modification of phytochemicals/synthesis of vitamins (13, 24, 25). 
Negative effects include diarrhea, intestinal putrefaction, infections, and potential 
carcinogen production (13, 25).   Generally, saccharolytic (carbohydrate) fermentation 
results in the production of short chain fatty acids and gas whereas 
proteolytic/putrefactive fermentation results in branched-chain fatty acids (BCFA) and 
potentially toxic ammonia, amines, phenols, indoles, cresols and sulphides (25).  
Selective stimulation of saccharolytic fermentation is suggested to be more beneficial 
than one that stimulates the metabolism of both carbohydrates and protein (24).  The 
current body of research suggests that the main saccharolytic species in the colonic 
microflora belong to the genera Bacteroides, Bifidobacterium, Ruminococcus, 
Eubacterium, Lactobacillus and Clostridium (24).  The main proteolytic species belong 
to the genera Bacteroides and Clostridium (24, 25).   
 
Traditionally recognized “beneficial” groups have included bifidobacteria and lactobacilli 
(18), but research is suggesting Eubacterium, Faecalibacterium and Roseburia species 
may also be included (24).  It is likely that additional bacterial groups related to positive 
or negative physiological functions in humans will be determined as more research is 
published using high throughput functional genetic testing.  Regardless, current research 
suggests that bifidobacteria and lactobacilli are beneficial and are the base of many 
probiotic supplements (26).  Bifidobacteria are saccharolytic organisms which produce 
lactate and acetate during heterofermentation of carbohydrates (via the “bifidus 
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pathway”) (27).  Although the products of fermentation from lactobacilli vary 
(homoferementation or heterofermentation) they are also considered lactic acid bacteria 
and primarily produce lactate or lactate and acetate (27).  These acids are thought to 
lower the pH of the fermentation area and potentially inhibit the growth of potential 
pathogens (13).  In addition to pH effects, some bifidobacteria produce antimicrobial 
substances (28).  
 
Species that belong to groups such as clostridia and Bacteroides have been recognized as 
potentially harmful (24).  Clostridia are of particular importance in this study, as 
Clostridium difficile is a frequent problem associated with occurrence of diarrhea in 
patients on enteral nutrition (29). When disruption of the normal flora occurs, C. difficile 
is able to overgrow and produce enterotoxins and diarrhea can result (26).  Some 
clostridia, however, are also able to further breakdown lactate produced in the colon to 
acetate, propionate and butyrate and is considered to be one of the major butyrate formers 
in the human intestine (30).  Bacteroides is a numerically dominant group of bacteria in 
the gut and represents approximately 30% of culturable fecal isolates (31).  Although the 
genus Bacteroides includes enterotoxigenic B. fragilis that is associated with diarrhea, as 
a whole the bacteria have diverse metabolic capabilities which contribute to more 
complete food digestion (32).  Conversely, decreased Bacteroides has been observed in 
patients with antibiotic associated diarrhea due to C. difficile (33). 
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Beyond determining which bacteria are associated with health, selective stimulation is 
difficult to measure since the growth of a particular group of bacteria is influenced by the 
initial numbers of bacteria present (34), dose, type of prebiotic and the complex 
interactions between the various intestinal microflora which occur in different regions in 
the gastrointestinal tract (15).   
 
In an attempt to examine a prebiotic model, quantitative data from 17 published and 
unpublished human intervention feeding studies which fed inulin-type fructans was meta-
analyzed to determine correlations between fiber, dose, and bifidobacteria increases (21).  
Although singular, the author targeted a bifidobacteria model since bifidobacteria exert a 
variety of health effects and comprise one of the dominant bacterial populations in the 
human large intestine (34).   From the data, daily dose of prebiotic did not correlate with 
the bacterial colony forming units per gram (CFU/g) differences, but the initial numbers 
of bifidobacteria did inversely correlate with the crude increases (21).  Other studies have 
also reported the inverse correlation between initial bifidobacteria numbers and “crude” 
increase (34-36).  Prebiotic index was introduced as “the increase in bifidobacteria 
expressed as the absolute number of ‘new’ CFU/g in feces divided by the daily dose (in 
grams) of prebiotic ingested” (21).  The prebiotic index proposed, therefore, is a 
bifidogenic index which reports the increase of fecal bifidobacteria in relation to the daily 
dose of prebiotic.  Although it was an overly simplistic model of prebiotic responses, the 
manuscript elucidated the complicated factors that influence how a fiber may be 
considered prebiotic.  For the bifidobacteria model, the initial size of the population 
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within the intestinal tract was inversely proportional to the response of the prebiotic i.e. 
those with small initial populations have a strong dose response while those with high 
populations (measured at 10
8
 CFU/g) did not increase their numbers further with 
increased fructan consumption (18). 
 
Enteral nutrition- definition, usage, formula types and complications 
Enteral nutrition (EN) typically refers to nutritional support that is delivered to the 
gastrointestinal tract through a tube, but can also be used to refer to “dietary foods for 
special medical purposes” that are administered via tube or oral supplements (37, 38).   
Enteral tube feeding is an effective means of offering nutritional support to those who are 
or are at risk of being malnourished in both hospital and community settings (29).  EN 
may be chosen for patients who do not or cannot eat adequately for a variety of medical 
reasons ranging from acute and chronic illnesses to those with swallowing disorders (39).  
Enteral feeding differs from parenteral feeding in that parental nutrition is the provision 
of nutrients intravenously (38).   
 
EN can be delivered via nasoenteric or percutaneous endoscopic gastrostomy or 
jejunostomy depending on the patient’s condition and needs (40).  Nasogastric feeding is 
preferred since it allows for normal digestive and hormonal processes (in the stomach and 
further) to occur (38).   EN is delivered to the patient via bolus, intermittent drip, 
continuous drip or a combination depending on the patient’s gastrointestinal function, 
tolerance to feeding and quality of life issues (40). 
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According to the latest annual statistics from the American Society for Parenteral and 
Enteral Nutrition, approximately 245,000 patients received EN in the hospital and around 
31,000 people received it in the home setting (41, 42).  With a large and diverse 
population receiving EN, a wide range of enteral products are available.  Formulas may 
be classified into nutritional categories, and choosing the correct product for a patient is 
based on the functional status of the patient’s gastrointestinal tract, the energy and 
nutrient needs of the patient, cost and other logistic considerations for the patient (29, 
40).  Intended to meet the nutritional needs of the general patient population, standard 
formulas are lactose free, contain intact proteins, carbohydrates and lipids, supply 1 
kcal/ml and are designed to meet the dietary reference intakes for vitamins and minerals 
of healthy adults (with volumes administered) (38).  Specialized formulas that are energy 
concentrated, high nitrogen, pre-hydrolyzed or chemically defined are also available for 
patients with specific dietary needs.  During EN, patient hydration should be considered 
since without an additional source of fluid, tube-fed patients may not receive enough 
fluids to meet their needs especially when energy concentrated formulas (1.5-2 kcal/ml) 
are administered (although fluid restricted patients differ). 
 
Complications of EN can vary from aspiration of formula to gastrointestinal disturbances 
to skin lesions if a percutaneous tube insertion is used.  The most common 
gastrointestinal complications include diarrhea, constipation, bloating and nausea and the 
occurrence rates of each vary depending on patient situation (length of treatment, etc.) 
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(39, 43). In hospitals up to two thirds of patients on EN have been reported to have 
diarrhea, but the lack of a standard diarrhea definition makes it unclear (39).  
Constipation is also an issue, but appears to be more associated with long term home EN 
(44).  Nausea also occurs, but is thought to be associated with abnormal gastric emptying 
(29).  EN associated gastrointestinal intolerance is a complex issue, and may be the result 
of multiple factors; feed delivery site/rate, feed type, concurrent laxative or 
antibiotic/drug therapies, small bowel bacterial overgrowth, Clostridium difficile 
infection, enzyme deficiencies (for example, lactase) and nutrient malabsorption (29).  
There is a potential interaction between some of these factors, dietary fiber and the 
colonic microflora. 
 
Fiber in enteral nutrition 
Fibers with various physicochemical properties have different physiological effects.  
Generally, less fermentable and/or insoluble fibers increase fecal bulk and/or hold water 
which facilitates colonic motor activity and promotes normal laxation (10).  Fermentable 
fibers are metabolized in the distal colon to produce SCFAs which through their 
absorption promote colonic fluid absorption and may prevent or ameliorate diarrhea-like 
symptoms (45).  SCFAs also decrease colonic pH which may favor the growth of non-
pathogenic bacteria (46).  Furthermore, fibers are a source of energy for gut bacteria and 
maintaining a normal (in health) flora provides competitive exclusion for potentially 
pathogenic organisms (e.g. C. difficile) and promotes bowel health (17, 47).  Despite the 
positive effects of fiber, contraindications do exist and some fibers may cause gas, 
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bloating and flatulence in individuals (48, 49).  Excessive doses of fiber may also cause 
diarrhea and reduced nutrient absorption (49).  Furthermore, when added to enteral 
formulas, fiber may cause blockages in small-bore feeding tubes and is typically the most 
problematic with highly viscous fibers (29, 49).  Sedimentation of fibers in the formula is 
also an issue (39).   
 
If the contraindications are minimized, a fiber enriched enteral formula may provide 
advantages over a fiber free formula.  Fiber supplementation to EN is not new, and in a 
2008 meta-analysis of fiber containing enteral formula studies that included 51 studies 
(43 randomized-controlled trials), fiber supplementation significantly reduced the 
incidence of diarrhea and was generally well tolerated (39).  Fiber supplementation to 
formula also moderated bowel function; fiber inclusion reduced bowel frequency when 
baseline was high and increased it when it was low (in both patients and healthy subjects) 
(39).  Furthermore, a fiber consensus panel recommended the inclusion of fiber in the 
diets of all patients if no contraindication exists, based on the benefits of diarrhea, 
constipation and feeding tolerance (50).   
 
Currently, there is no agreement on the best fibers to add to enteral products (39), and no 
recommendations exist for fiber intake in several disease states or in patients in long term 
care facilities (49).  Recommendations from the European Society of Parenteral and 
Enteral Nutrition suggest adding fiber to EN at a rate of 10-15g/L (37).  Other enteral 
guidelines suggest 15-30 g/day for patients on EN if no contraindications exist (37, 39).  
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For reference, in the United States, the Institute of Medicine recommends that adults (50 
years or younger) consume 38 g (men) and 25 g (women) (3).  For those over 50, the 
recommendations are 30 and 21 g, respectively, due to a decreased energy need.  The 
average usual intake of an American is 14-15 g per day (51).   
 
Effects of dietary fiber on gut function 
Brief overview of foodstuffs through the gastrointestinal system  
Fiber travels through the gastrointestinal (GI) system intact in foods or as an isolated 
source.  Substances enter the GI system through the oral cavity, are mixed with saliva and 
enzymes and quickly travel to the stomach.  In the stomach, foodstuffs are exposed to a 
low pH, enzymes, and come in contact with a relatively low load of microbes (in health) 
with 10
2
 CFUs per milliliter (ml) of contents (52).  Within minutes, the contents of the 
stomach are propelled to the small intestine where it is mixed with pancreatic and biliary 
secretions, the pH increases and the microbial loads increase.  In the duodenum (first 
section of the small intestine), the microbial load rises to 10
2
-10
4 
CFU/ml contents (53) to 
the ileum where 10
6
-10
8
 CFU/ml contents have been found (54). The small intestine is 
the main site of nutrient and water absorption with transit time through the stomach and 
small intestine taking an average of 4-6 hours in health (47).  The undigested foodstuffs, 
digestive substances, and sloughed off cells are then propelled to the large intestine.  The 
large intestine, or large bowel, is the main site of microbial colonization in the gut and 
harbors approximately 10
11
-10
12
 bacteria per gram of intestinal contents (47, 55).   
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Metabolism of fiber by microbes does not exclusively occur in the large intestine, but is 
the primary site of utilization.   Bacterial metabolism includes fermentation of 
carbohydrates and proteins, and a variety of compounds including (but not limited to) 
flavonoids, heterocyclic amines, and bile acids (56).   The large intestine is hallmarked by 
long residence times (up to 60 hours), a more neutral pH and anaerobic environment (47).  
Endogenously, the primary function of the large intestine is to store and concentrate 
undigested matter through the absorption of salt and water.  Water absorption in the GI 
tract is passive and although the small intestine absorbs the majority of water, the colon 
has a large absorption capacity as well.  If exceeded, or without sufficient time to absorb, 
watery diarrhea may occur (57).  Upon completion of digestion and absorption, feces are 
eliminated.  Fecal matter is complex and is composed of approximately 75% water, and 
varying amounts of bacteria, unfermented fiber residue, inorganic substances, bacterial 
fermentation products and undigested protein, cells and bile pigment (with estimates that 
bacteria contain 7% of the dry weight) (10, 47).   
 
Stool weight and whole gut transit time 
Stool weight is currently the most direct biomarker of total fiber intake.  Stool weight is 
influenced by the presence of fiber, by the water the fiber holds, increases in bacterial 
biomass if the fiber is fermented, gut transit time and abnormalities in fecal moisture (49, 
58).  Laxation studies have also found significant differences in stool weight between 
genders and personality types, suggesting that other factors play a role in stool weight 
(59-61).   In general, there is a positive correlation between fiber and stool weight, 
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although fibers that differ in fermentation characteristics and/or particle size affect stool 
weight to different degrees (58, 61-63). Smaller stool weight increases have been 
observed with highly fermentable fibers such as pectin or mixed fruit and vegetable fibers 
compared to wheat bran (less fermentable) despite a similar dose, although the fibers also 
differed in particle size (64).  A similar trend was observed when feeding wheat bran and 
a mixture of pea fiber, soy polysaccharide and pectin in a liquid diet base; wheat bran 
increased wet stool weight more than the vegetable fiber, although increases were seen 
with the vegetable fiber compared to the fiber free control (65).  Studies suggest the 
smaller stool weight increases seen in more fermentable fibers is due to the loss of 
structure as the polysaccharide is digested which affects its water holding 
capacity/viscosity (61, 66).  Stool weight increases observed in fermentable fibers are 
through increased bacterial mass that occurs with growth (58, 62).  Fiber particle size also 
influences stool weight, and human feeding studies conducted with wheat bran observed 
a larger stool weight increase with larger particle sizes (6, 67). 
 
Gender differences have been observed in stool weight; women were found to have 
smaller stool output than men and have a smaller stool weight increase as compared to 
men (61, 64). 
 
The time required for substances to travel from ingestion to defecation is generally 
referred to as transit time, gastrointestinal transit time or whole gut transit time (WGTT) 
(68, 69).  Since most of the WGTT reflects passage through the colon, WGTT 
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measurement techniques are an approximation of colonic transit time (70). Fecal weight 
is negatively correlated with transit time, although dietary fiber intake has a more 
inconsistent correlation, which may reflect the varied physicochemical properties of fiber 
(63, 67, 71).  Fecal bulk is thought to increase colonic motility, while short chain fatty 
acids produced through fiber fermentation are also thought to play a role in increased 
colonic motility (decreased transit time) (72, 73). Whole gut transit time influences 
bacterial growth and water absorption; the longer feces remains in the large intestine, the 
more water may be absorbed and the fewer bacteria that are excreted (71). Similar to 
fecal weight, there is a large variability in gut transit time between individuals and intra-
individually (61, 62, 64).   
 
Constipation and diarrhea are two extremes of bowel function that are related to stool 
weight, transit time, and fecal moisture.  Etiology of these conditions is vast and neither 
have a consistent definition in the literature.  Constipation has been defined as three or 
fewer spontaneous bowel movements per week (74), stool weights of less than 100 g/day 
(75), and/or hard stool that retains its shape, with difficulty in defecation or patients 
requiring laxatives/enemas” (39). Constipation may occur when fecal matter remains in 
the large intestine for an extended period of time and becomes hard, dry and difficult to 
pass (76).  Diarrhea is typically characterized by large, frequent, watery stools and can 
result from decreased fluid absorption, increased fluid secretion, or both (76).  Another 
definition includes elevated stool output (>200 to 250 g/day) that is watery and difficult 
to control with more than three bowel movements per day (77).  Normal transit time has 
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been defined as producing between three stools per day to three per week with an absence 
of diarrhea and constipation (78, 79). 
 
Fecal weight measurement techniques vary based on the length of time stool samples are 
collected, and common periods are 1-10 days (62, 80, 81). Ideally, a fecal sampling 
procedure collects multiple replicates, allows for tandem gut measurements if necessary, 
and has the least possible subject burden.  Longer sampling protocols allow for a more 
representative sample (versus 1 sample) of the individual’s stool pattern since daily stool 
weight intra-individual variation has been observed to be as much as 100% or more (63).    
Furthermore, stool weight, when combined with fecal moisture and other subjective 
measures, may indicate diarrhea or constipation (39).   
 
Various measurement techniques have been utilized to measure whole gut transit time. 
Free dyes may be consumed and the color appearance tracked in the fecal sample; dye 
recovery can be affected by fiber content, however, and may not reflect gut movement 
when fiber is low (82).  Fiber mordants may be synthesized, but mordants are not 
possible with all fibers (67).  Radio labeled substances that mirror the transit of fiber may 
be used to track transit through each region of the GI, but are expensive and require high 
subject burden (70).  Similarly, wireless devices track digest transit through the entire GI 
and additionally measure pressure, pH, and temperature (70).  Such devices are costly 
and measurement is influenced by the timing of the capsule and test meal administration 
(70, 83).  Although it does not provide regional gastrointestinal information, measuring 
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whole gut transit time with radio-opaque markers provides a relatively inexpensive and 
low participant burden method (70, 84).  Markers may be taken continuously or as a 
bolus, and fecal samples are then recovered and pellet content is determined by x-ray (84, 
85).  Previous recovery studies have shown that normal individuals retain less than 80% 
of pellets of a 20 pellet dose within 5 days (86).  Using a bolus dose, whole gut transit 
time may be calculated based on the time to excrete 80% or as mean transit time (a 
weighted average of pellets over time) (82, 84).  Comparing the 80% transit time and 
mean transit time calculation techniques, both have similar variability and yield 
comparable results (82).   
 
Several studies administering a polymeric oral enteral formula to healthy subjects (both 
fiber free and fiber blend) observed an approximate 50% decrease in daily stool weight 
compared to a self selected diet (48, 79, 87).  This was observed despite a higher daily 
fiber intake on the fiber containing liquid diets than the self selected diets.  In one study, 
addition of 60 g of soy fiber to the liquid base diet was required to increase stool weight 
to similar self-selected diets (79).  In regard to formula comparison, a blend of soy fiber, 
cellulose, gum acacia, inulin, oligofructose, and resistant starch added to a fiber formula 
(daily intake 30 g/day), did not increase stool weight compared to a fiber free formula 
(87).  Daily average stool weights were 95 g on the fiber formula and 97 g on the fiber 
free (79).  Another study fortifying with a blend of fructo-oligosaccharides and pea fiber 
(average 16.5 g/day), measured stool weights at 44 g/day on fiber free formula and 73 
g/day on fiber supplemented formula (although the differences were not significant) (48).        
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As measured by radio-opaque pellets, Slavin et al found that transit time on fiber free 
enteral formula was 72.4 h and approximately 48 h during both the soy fiber 
supplemented enteral and self-selected diets (79).  Another study using a blend of soy 
fiber, cellulose, gum acacia, inulin, oligofructose, and resistant starch in the fiber formula 
measured a shortened gut transit time compared to fiber free formula (76 h fiber free and 
50 h fiber blend), but both were longer than the habitual diet transit time of 46 h (87).  
Although not directly transit time, addition of fructo-oligosaccharides and pea fiber to an 
enteral formula increased fecal frequency (number of stools/day) compared to the fiber 
free formula.  Mean fecal frequency of this study was 1 per day on habitual diet, 0.6 per 
day on standard fiber free formula and 0.9 per day on fiber formula (48).     
 
Stool form and fecal moisture 
Stool form is a visual estimation of stool consistency which is generally “measured” by 
comparison to a chart that includes pictorial and verbal descriptors (88).  Some stool form 
charts also include information for estimating stool weight (89).  A more objective 
measurement of stool consistency may be achieved with fecal moisture or rheological 
assessments (90). Stool formed-ness has been correlated with whole gut transit time and 
can be used to monitor changes in colonic function (91).  While whole gut transit time 
may affect fecal moisture, fecal consistency is related to both water content of the stool 
and the water-holding capacity of the fecal insoluble solids (90). Fiber affects stool 
consistency and moisture through its physiological effects on transit time and its 
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physicochemical properties and particle size which affect water holding capacity.  Fecal 
moistures of healthy subjects consuming normal diets without constipation or diarrhea 
are approximately 70-80% moisture (wet basis) (63, 65, 67).  In a stool form validation 
study, water content of fecal samples correlated with a four category scale of formed-
ness; hard and formed-62% moisture, soft and formed-72% moisture, loose and 
unformed-79% moisture, liquid-87% moisture and all were significantly different (88). 
Furthermore, the ratio of fecal water to fecal solids increased only slightly in stool 
weights of healthy subjects despite stool weights ranging from 39 to 235 g/day (90).  The 
apparent consistent water/solid ratio in fecal samples may be due to a considerable 
amount of fecal water contained within fecal bacteria that is unavailable for absorption 
(only free fluid is available for absorption) (57, 90).  In patients with chronic diarrhea that 
have high moisture stools, but normal stool weight, it was observed that low or low to 
normal fecal insoluble solids were present (90).   
 
Several manuscripts describe categorizing fecal samples into consistency categories 
which are typically author defined and vary in number of categories from two to up to 
twelve (65, 89, 91, 92).  Two common stool charts which have been used extensively 
include the King’s stool and Bristol stool chart (89, 91).  Both scales have been validated 
in various studies (88, 89, 93-95).  The King’s chart organizes stool into 12 categories 
using pictorial and verbal descriptors to determine consistency and stool weight (89).  
The Bristol stool chart was developed to assess stool form in relation to changes in transit 
time in healthy adults and organizes stool into seven types using pictorial and verbal 
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descriptors to determine consistency.  Each consistency is assigned a numerical value 
ranging from 1 (most formed) to 7 (least formed) (91). 
 
Moisture determination methods vary widely, and several methods are suitable for 
determining fecal moisture.  Drying methods utilize ovens or infrared to heat the sample, 
evaporate the water, and measure weight loss (assumed to be all water) to determine 
moisture content.  Heat drying methods are subject to bias as volatile components (such 
as short chain fatty acids) are lost, carbohydrates decompose at the temperature and time 
utilized and incomplete moisture removal may occur due to form of the water present 
(free, adsorbed, water of hydration) (96).  Drying methods are simple, allow for 
simultaneous analysis of large number of samples, and specialized equipment is not 
required; some laboratories utilize this method for fecal moisture (97, 98).  Freeze drying 
methods are also applicable.  Samples are frozen, placed into a freeze dryer where the 
pressure is reduced to allow the frozen water to sublimate.  Freeze drying requires similar 
(or more) time as drying methods, requires specialized equipment and sample throughput 
is not as high volume.  It has also been used in determining fecal moisture (99).  Infrared 
spectroscopy (IR) has also been used to determine moisture in fecal samples (100).  IR is 
based on the selective absorption of electromagnetic radiation of functional groups (such 
as –OH in water) since each as a characteristic vibration frequency (96).  IR requires 
specialized equipment.  Overall, a forced draft oven is an inexpensive and non-labor 
intensive method that doesn’t require solvents or specialized equipment. 
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In enteral studies examining the effects of fiber addition on fecal consistency and 
moisture in healthy subjects, the results have been mixed.  Enteral formula supplemented 
with hydrolyzed guar gum (101), soy fiber (79) or pectin (102) resulted in a more 
normally formed stool than either a hard/dry or liquid stool in the fiber free formulas.  In 
other studies using guar gum (103) or soy polysaccharide (104), no consistency 
differences were found.  As far as those studies that also measured fecal moisture, Lampe 
et al observed that fecal moisture on a self selected diet was the same as the enteral diet 
supplemented with soy fiber, but higher than both fiber free and guar fortified formula 
(104).  Another group examining dose of soy fiber in enteral formula did not see 
statistically significantly different fecal moistures, but the values appear to slightly 
increase as fiber increased; self selected-72%, no fiber-75%, 30g-75% and 80% for 60 g 
(79).  Finally, adding a blend of fructo-oligosaccharides and pea fiber to enteral formula 
did not affect fecal moisture – no differences were found between habitual diet, fiber free 
formula or fiber supplemented formula (48). 
  
Short chain fatty acids and pH 
The production of SCFA in the gut is dependent on the type of substrate available, the 
amount of substrate, the transit time (retention time of substrate), the composition of the 
bacteria, and the characteristics of the bacterial groups present (enzymes, optimal growth 
pH, etc.)(105).  Gut bacteria ferment non-digestible carbohydrates and proteins arriving 
from the small intestine although protein fermentation is dependent on the amount of 
carbohydrate available (105, 106).  If sufficient carbohydrates are available, protein 
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fermentation is reduced while protein fermentation is favored if carbohydrates are 
insufficient (107).   Carbohydrates for fermentation are mostly derived from the diet, 
while protein is from both dietary and endogenous sources (enzymes, mucus and 
exfoliated cells) (106, 108).  Carbohydrate fermentation results in lactate, ethanol, 
pyruvate and succinate production in some species, but as a whole gut, these can be 
subsequently used by other bacteria and the major end products are the short chain fatty 
acids acetate, propionate and butyrate (56).  Protein fermentation yields branched chain 
fatty acids, ammonia, amines, phenolic and volatile sulfur compounds (56). Other 
fermentation products such as caproate and valerate also occur, but in lower amounts 
(24). SCFA are thought to be readily absorbed in a normal colon via both nonionic 
diffusion and ionic exchange and up to 95% of SCFA are thought to be absorbed from 
colonic contents (45, 109).    
 
As a whole, SCFAs reduce fecal pH, affect colonic moisture, inhibit pathogen growth, 
provide energy to the host, and may affect gut transit time (24, 46, 72, 110).  SCFAs may 
also have roles in inflammation, mineral absorption, and improvement of barrier function 
which may prevent the translocation of bacteria and toxins from gut to system (24, 39).  
SCFA absorption by colonic epithelial cells stimulates sodium dependent fluid 
absorption, which affects fecal moisture and benefits those with diarrhea (45, 111). 
SCFAs are also thought to affect gut transit time.  Using a rat model, physiological 
concentrations of SCFA increased motility and accelerated colonic transit which was 
suggested to be due to the release of serotonin in response to the SCFA (72, 73). 
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Individually, butyrate is the preferred form of fuel for colonocytes and most is oxidized 
in the colonic mucosa during absorption (109, 112).  Butyrate also plays a role in 
epithelial intestinal cell differentiation and proliferation (113).  Propionate is absorbed, 
partially utilized by the colonocytes depending on the availability of butyrate, and then 
utilized by the liver (112, 114).  Propionate has also been proposed to influence 
cholesterol synthesis (115).  Acetate is absorbed and utilized by the liver and/or enters the 
systemic circulation for use by muscle and adipose depending on the metabolic state 
(116). Acetate is the major acid entering systemic circulation (115, 117). 
 
The pH of the colonic lumen is in part determined by host secretions and in part by the 
acidic fermentation products of gut microorganisms.  Using telemetry it has been 
observed that the proximal colon generally has a lower pH than the contents of the distal 
colon and feces (118).  The pH spectrum in the colon is thought to be due to the 
fermentation of dietary substances (producing acidic compounds) as they travel through 
the colon (119).  Intake of fermentable carbohydrates has been observed to decrease fecal 
pH, and it is hypothesized that colonic pH fluctuates depending upon dietary intake 
(118).  Colonic pH influences the solubility of bile acids, ammonia and minerals as well 
as affecting gut bacteria growth and activity (46, 110, 118).  Each type of bacteria has an 
optimal pH and reductions in pH may increase or decrease bacteria (depending on the 
type), which in turn affects the profile of SCFA produced (46, 118, 120).   In an in vitro 
system utilizing human fecal donors, growth of Bacteroides and pathogenic E. coli was 
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inhibited by a pH of 5.5 and E. coli was further inhibited when SCFAs were added to the 
growth medium (118).  Conversely, butyrate producing Eubacterium represented 50% of 
the microbes present at pH 5.5, but was not detected at pH 6.7 when Bacteroides 
dominated at 86% of microbes present (118).  These results were corroborated with 
another in vitro study measuring increased butyrate at pH 5.5. versus 6.5 (46). 
 
In humans, SCFAs may be measured from colonic contents, fecal samples or in the 
blood: due to the subject burden (in healthy subjects) and ethical issues, most are 
collected from feces or blood (105). SCFA in fecal samples represent residual amounts 
after production and absorption in the gut which is thought to be approximately 5-10% of 
SCFA that is produced.  Since SCFA production varies depending on the fermentability 
of the substrate, amount and retention time of the substrate, bacterial populations present, 
and absorption may be affected by concentration, fecal SCFA provide little specific 
information about each of the influences (105).  Blood SCFA, however, have similar 
drawbacks.  SCFA are produced, absorbed and utilized by the colonocytes in varying 
amounts, utilized by the liver in varying amounts and finally enter the bloodstream (112).  
Timing of blood samples is also important as fatty acids are cleared from circulation 
(112). 
 
Beyond the challenges of collecting a representative samples containing SCFA, sample 
preparation and analysis are not consistent in the literature.  Methods include fecal water 
separation and analysis by liquid chromatography (121) or gas chromatography (99), 
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distillation of fecal samples and analysis by gas chromatography (122), and fecal 
extraction via solvent and analysis by gas chromatography (123).  Regardless of method, 
it is important to note that SCFA are volatile and weak acids with pKa’s approximately 
4.8 making nearly all SCFA found in stool samples present as anions rather than free 
acids (112).  Solubility due to chain length differences has also been found (124).   
Overall, measurement of SCFA in human samples via feces or blood reflects residual 
values after production and absorption.  Finally, although ratios of the various SCFA is 
relevant when studying the effects of chemical and structural features of fiber on the 
production of SCFA, the absorption processes of individual acids may confound the 
measurement and values obtained may not reflect production levels within the gut.   
 
Fecal pH is measured using a calibrated probe (48, 125).  Since fecal samples are not 
homogenous, samples should be mixed before measurement.  
 
In healthy subjects consuming enteral nutrition with and without fiber, the SCFA and pH 
results have been mixed.  Total SCFA in fecal samples significantly decreased when 
consuming enteral formula compared to habitual diet in two studies (48, 102), while 
another study found no statistically significant difference between normal diet and enteral 
diets (although the values were lower) (104). Between fiber free or fiber containing 
formulas, a fructo-oligosaccharide and pea fiber containing formula had higher total fecal 
SCFA than fiber free (48), a pectin fortified formula had higher total SCFA than fiber 
free (but was not statistically significant) (102), and a soy or guar gum fortified formula 
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was not different than fiber free (104).  Another study measured SCFA in the plasma and 
found no differences between a fiber free formula and one containing hydrolyzed guar 
gum (101).  Generalized comparison between enteral studies for SCFA production is 
difficult due to various fiber sources used (different fermentabilities), and differing 
sample techniques and analysis methods. 
 
There is more agreement in measuring pH.  Three studies found normal diet to have 
significantly lower pH (all approximately a pH unit lower) than when consuming enteral 
formula (48, 102, 104).  Subjects consuming pectin, guar gum, or soy fiber fortified 
formula did not have a different fecal pH than when on fiber free formula (102, 104).  
Consumption of a formula fortified with blend of fructo-oligosaccharides and pea fiber, 
however, led to a significantly lower fecal pH than the fiber free formula (48). 
 
Subjective tolerance 
A common side effect of fiber ingestion is “gas”.  Gas, however, may be from swallowed 
air, production within the gut, or diffusion from the blood (126) and is composed of 
nitrogen, oxygen, carbon dioxide, hydrogen, and methane (127).  Gas production in the 
gut may be produced via acid reaction with bicarbonate to liberate carbon dioxide, or 
from fiber fermentation by bacteria in the gut (producing hydrogen, carbon dioxide, 
methane and hydrogen sulfide gases) (115, 127).  An endogenous source of acid is gastric 
acid, while acids are also produced by the gut bacteria during fiber fermentation.  If gas is 
produced in sufficient amounts, it may cause bloating and flatulence in individuals (128).  
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Gas may be eliminated via diffusion into the blood, metabolism by gut bacteria and/or 
passage via the rectum (126) .  Symptoms commonly attributed to “gas” are belching, 
bloating, abdominal pain, and excessive flatulence (127).   
 
In addition to tolerance of fiber side effects in the diet, exclusion consumption of enteral 
nutrition (in patients) has been associated with several gastrointestinal side effects; 
diarrhea, constipation, nausea and selective bacterial overgrowth (29).  Furthermore, in 
studies examining healthy subjects converting to a liquid diet, subjects experienced 
changes in bowel habits (48, 79) which may influence quality of life (129). 
 
Various fiber feeding studies monitor gastrointestinal side effects, although many do not 
cite previously published methods to do so.  A validated gastrointestinal symptom scale is 
The Gastrointestinal Symptom Rating Scale (130).  Many tools exist to monitor generic 
quality of life as well – Nottingham Health Profile and the Centers for Disease Control 
and Prevention’s Health Related Quality of Life to state a few (131).  One index, the 
Gastrointestinal Quality of Life (GIQLI) measures both quality of life and gastrointestinal 
symptoms (132).   Using 36 questions, the GIQLI measures overall quality of life related 
to gastrointestinal wellness and inquires about side effects related to digestion and 
defecation as well as physical and mental well-being.  In particular, the questionnaire 
assesses the frequency of gas/bloating, abdominal pain, reflux, diarrhea/urgent bowel 
movements, constipation, nausea, and reflux.  The GIQLI is a validated questionnaire that 
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has been used in previous enteral studies (129) and in the original version was 
administered to normal individuals to assess validity. 
 
Although widely monitored, tolerance of exclusive enteral formula administration (via 
oral consumption) in healthy humans has been mixed.  Slavin et al found no differences 
in symptoms of nausea, cramping, diarrhea, constipation and diarrhea between habitual 
diet, fiber free enteral formula and enteral formulas containing up to 60 g soy 
polysaccharide (79).  Lampe et al found that subjects had increased reporting of water 
stools, anal burning during defecation and gas with the fiber free formula and modified 
guar formula, but not with soy supplemented formula.  Objective measurements of fecal 
moisture in the same study, however, did not corroborate the subjective reported side 
effects (104).  Examining fructo-oligosaccharide and pea fiber added to formula, Whelan 
et al found that gastrointestinal symptoms were not increased on either enteral formula 
compared to habitual diet and flatulence decreased on fiber free formula compared to 
habitual diet.  Between the formulas, nausea incidence and severity was increased on 
fiber formula while flatulence incidence and severity was increased on the fiber formula 
(48).  Silk et al found no adverse gastrointestinal effects while on a normal diet but 
between formulas, the fiber formula containing soy polysaccharides, cellulose, gum 
acacia, inulin, oligofructose and resistant starch had less nausea and bloating than the 
fiber free formula.  Additionally, all but 2 subjects developed headaches when first 
transitioning to the enteral diet (regardless of fiber or fiber free) although the symptoms 
subsided within a few days and did not reoccur during the second enteral diet (87).  
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Finally, two subjects on fiber free reported watery stools and two subjects on the fiber 
free formula reported feeling constipated.  No diarrhea or constipation was found during 
the fiber enriched enteral formula (87).   
 
Gut microbiology 
Eukaryotes, Bacteria, and Archea may be found in the up to 10
12
 microorganisms per 
milliliter of human large intestine contents (47, 55).  Of these domains, Bacteria 
predominate (133).  The overall population and constituent groups of the bacteria are 
important for competitive exclusion of pathogens, short chain fatty acid production (i.e. 
complete food digestion and energy production), and enhanced immune function (not 
addressed in this study) (134, 135).  Although the human colonic bacterial community 
differs between individuals (136-138), it is represented by four main phyla: Firmicutes, 
Bacteroidetes, Proteobacteria , and Actinobacteria (17, 133, 139).  In general, Firmicutes 
and Bacteroidetes make up the dominant portions of the colonic bacteria (140).  Recently, 
personal “enterotypes”, or proportions of bacteria as determined by 16S rDNA 
sequencing have been found to be relatively stable in individuals with consistent long-
term dietary habits (136).  Earlier studies utilizing temperature gradient gel 
electrophoresis of 16S rRNA on fecal samples have also observed stability of dominant 
groups of bacteria over the course of 6 months (141).    
 
The gut bacterial population is affected by the type and amount of fermentable substrates 
(diet), exogenous bacteria, concentrations of antimicrobial substances, ionic and pH 
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conditions, and gut transit time (13, 72, 118, 136).   Those with long term protein and 
animal fat based diets are associated with the Bacteroides (Bacteroidetes) enterotype and 
carbohydrate diets with Provotella (Bacteroidetes) (136).  Prebiotic fibers such as 
fructans are known to increase Bifidobacteria (142-144).  Exogenous bacteria consumed 
in fermented foods such as yogurt also modify the gut bacteria and fecal bifidobacteria 
levels were increased in subjects consuming fermented dairy products within a few days 
(145).  Additional host factors found to influence gut microbe composition are many.  
Body mass index has been observed to affect the gut microbes as the gut bacteria of 
obese adults have fewer Bacteroidetes and more Firmicutes than lean counterparts as 
demonstrated by a human study (146).  Additionally, a cross-sectional study utilizing 
fluorescence in situ hybridization on 230 subjects observed that Enterobacteria was 1.7 
times higher in elderly (>60 yr.) compared to younger adults suggesting that age may be a 
factor in gut ecology.  This same study also found a significant difference by gender with 
males having higher levels of Bacteroides-Prevotella group than women (147).  Data is 
limited on menstrual status of females and gut microbiota although a study observed that 
post-menopausal women had higher fecal clostridia levels than fertile women (148).    
Individual genotype also influences gut bacterial populations; monozygotic twins had 
fecal bacteria profiles (determined by denaturing gradient gel electrophoresis) that were 
significantly more similar than those for unrelated individuals.  The same study observed 
that marital partners living in the same environment with comparable feeding habits had 
low similarity (149).  Antibiotic usage is also known to affect gut microbes (150) as well 
as host diseases (151).   
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Further complicating the large and diverse population in the gut, the bacteria are not 
evenly distributed and micro-habitats include the lumen, mucous layer, crypts and surface 
of the epithelial cells (152).  Although many sampling techniques are based on fecal 
samples, biopsies may also be performed to observe mucosal associated bacteria (151). 
 
At present, methods exist to identify bacteria present, enumerate specific groups or 
profile the microbial diversity in samples and all have advantages and disadvantages. 
Until recently, our knowledge of the human gut microbiota was based on conventional 
microbiological culturing techniques, which are currently estimated to measure 15-54% 
of the microbial diversity in a fecal sample due to the inability to culture the bacteria 
(unknown growth requirements/restriction factors), microbe death and microbe viability 
(17).  Cultivation methods have also been used to characterize and/or identify bacterial 
colonies based on morphological and biochemical traits, but these can be unreliable and 
time consuming (153).   
 
Although originally used in conjunction with bacterial cultivation, molecular approaches 
based on the bacterial ribosomal RNA gene are extensively used (139).  The 16S rRNA 
gene is universally distributed in bacteria, has a slow rate of evolutionary change, and 
contains various regions with different degrees of conservation (153).  A highly 
conserved genetic region of the rRNA may be targeted in experiments (using “universal” 
primers) to measure or probe for all bacteria.  Other variable or hypervariable regions of 
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the rRNA may be targeted to yield information about genus or species of bacteria (18).  
In some instances, the rRNA sequence may be highly conserved within a genus and the 
use of the internal transcribed spacer region between the 16S and 23S rRNA genes or 
other specific genes may be used (154). 
 
The most basic culture independent method is a direct microscopic analysis of all bacteria 
present.  Bacteria from fecal samples are heat fixed onto a surface, stained (typically with 
DNA staining fluorescent 4’,6-diamidino-2-phenylindole-stain “DAPI”) and enumerated 
to give total cell counts (138).  With this technique, cell detachment may occur, and cells 
may differ in stain uptake (154).  Other culture independent methods can be divided into 
molecular probing without polymerase chain reaction (PCR) and PCR based strategies.  
 
As an aside, indirect analysis of gut microbes may also be considered a culture 
independent method.  Functional measurements, such as short chain fatty acids 
(fermentation products) or enzyme analysis provide information on the metabolic 
activities of the microbial community, but used alone yield vague information regarding 
the groups of bacteria present (154).  
 
Molecular probing methods that do not utilize PCR may be used to detect, enumerate, or 
assess activity of bacterial groups present in gastrointestinal samples (139, 155).  
Molecular probing techniques involve the hybridization of a specific sequence of 
oligonucleotides (“probe”) with a target sequence of bacterial DNA or RNA that is able 
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to be detected when hybridized to the target.  Examples include dot blot assays and in situ 
hybridizations.  In dot blot assays total RNA is isolated from a sample, immobilized onto 
membranes and then hybridized with universal and specific probes.  The assay is able to 
detect bacteria and provide a relative concentration (abundance) (155).  The numbers 
obtained are relative quantification since cells of different species have different 
ribosome contents and the ribosome content also varies with growth rate (156).  
 
Whole cell in-situ hybridization is commonly coupled with fluorescently labeled probes 
and appropriated called fluorescent in-situ hybridization (FISH).  With FISH, bacterial 
cells are permeabilised and probed with labeled 16S (or 23S) rRNA targeted 
oligonucleotides.  If the cell’s rRNA contains a complementary sequence to the probe, a 
hybrid is formed and the cell will be visualized.  Each active cell typically contains 
several thousand ribosomes, and the fluorescence can be visualized and enumerated by 
fluorescent microscopy or flow cytometry (153, 155).  When coupled with fluorescent 
microscopy, whole bacterial cells are fixed onto a slide, and method detection limits are 
estimated at 10
4
- 10
6
 bacteria per gram stool sample (17, 157).  Using flow cytometry, 
whole cell hybridization techniques may have a limit of detection around 10
4
 CFU/ml 
(17).  Additional limits of FISH include differences in cell wall permeability and 
subjectivity in low fluorescent signals (139, 157, 158). 
 
PCR is a molecular technique used to amplify a targeted DNA sequence in an exponential 
manner.  Because PCR exponentially increases DNA sequences, methods are able to 
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detect sequences in low concentrations (155).  PCR, however may be biased from 
incomplete nucleic acid extraction, variable gene copy numbers, amplification cycle 
numbers, cell viability, and indiscriminate detection of genes (139, 155, 159).  For gut 
microbiology, PCR based strategies have been developed to profile bacterial 
communities and detect, identify and/or enumerate bacteria present (139, 153, 155). 
Using PCR, 16S rRNA genes may be amplified and the resulting amplicon separated 
based on melting temperature (temperature gradient gel electrophoresis-TGGE) or 
chemical stability (denaturing gradient gel electrophoresis-DGGE) to generate bacterial 
community fingerprints (158).  PCR-DGGE or TGGE yields a profile of bacterial groups 
present and although one band is supposed to correspond to one species, co-migration 
may occur (158).  Bands may also be excised and sequenced to identify species (139).  
Another type of community profiling is terminal restriction fragment length 
polymorphism (TRFLP).  Again, the 16S amplicon is generated but is then digested and 
the fragments are separated to visualize the community fingerprint (158).  Profiles 
obtained in these methods are representative of the primer used:  a universal primer will 
produce a broad view of the community, while a more specific primer (such as one that 
targets bifidobacteria) results in a specific community profile.  In addition to the biases of 
PCR, TRFLP encounters additional bias of the restriction enzyme specificity (158). 
Besides profiling, 16S amplicons may be cloned and sequenced to identify the bacterial 
community present.   Identification using clones and 16S sequencing is laborious and 
expensive –especially for monitoring a community (139).  
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By using quantitative PCR (real-time or competitive), quantification of target bacterial 
DNA or RNA can be achieved. In real-time, a fluorescent system is used to monitor and 
quantify the accumulation of amplicons during PCR.  In theory, the fluorescence signal is 
proportional to the accumulation of amplicons, and by relating the fluorescent intensity 
with that of known amounts of target DNA, an extrapolation of the initial quantity of 
DNA (or RNA in the case of reverse transcriptase) is possible (158).  In addition to PCR 
biases, the fluorescent dye may be non-specific and different methods of standard curve 
generation may affect the outcomes (158).  
 
To correct for sample-to-sample variation resulting from PCR inhibitors or extensive 
background DNA, competitive qPCR utilizes a co-amplified internal standard to calculate 
the ratios of target amplicons to competitor amplicons (155, 158).   
 
Other PCR based methods include microarray or membrane array techniques.  For this, 
multiple 16S rDNA probes targeting a panel of fecal bacteria species (or specific genes) 
are pre-immobilized on a surface.  The microbial genetic material of the sample to be 
tested is amplified, added to the surface to hybridize with the probes present, and then 
visualized to detect and/or estimate the relative abundance of bacteria present (139).    
 
Most recently, techniques have been developed to examine the gut environment via 
“meta-omics” approaches.  In a metagenomic approach, the genetic material of all 
bacteria present in a fecal sample is extracted and either cloned and sequenced or directly 
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sequenced to characterize and quantify the bacterial taxa present (158, 160, 161).  Instead 
of determining the microbial genes present, meta-transcriptomics inventories the genes 
that are being expressed by isolating the transcripts (RNA) of a sample, synthesizing the 
complimentary DNA and then proceeding as in the metagenomic approach (158).  
Transcriptomics provides information about actively expressed genes to determine 
functional properties of the gut population (162).  Both methods are limited by nucleic 
acid extraction techniques, cloning and/or sequencing and the difficulty of linking genetic 
sequences to microbes (158).   
 
Few studies on healthy subjects consuming enteral nutrition have measured gut bacteria 
with any method.  In a study on 10 healthy subjects, total fecal bacteria (measured via 
FISH) was significantly decreased on both enteral formulas (fiber fortified or fiber free) 
compared to habitual diet (48).  Furthermore, between enteral formulas, total bacteria 
were increased on the fructo-oligosaccharide and pea fiber containing formula compared 
to the no fiber formula.  Bifidobacteria was significantly increased on fiber formula 
compared to both fiber free formula and habitual diet.  Clostridia were decreased on fiber 
formula compared to habitual diet, but not fiber free formula.  No differences were found 
between any diet for populations of Bacteroides (48).   
 
Another study comparing patients on enteral nutrition to healthy controls, bifidobacteria 
levels were 10 fold lower as measured by quantitative PCR in patients on enteral nutrition 
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regardless of receiving fiber free or fiber enriched (oat, soy, gum acacia, 
carboxymethylcellulose and fructo-oligosaccharides) formula (129). 
 
Fructo-oligosaccharides and inulin 
Fructo-oligosaccharides (FOS) and inulin are “inulin type fructans” (ITF).  Fructans can 
also be levan or graminan types which are primarily found in microbes or grasses, 
respectively.  The various fructans are distinguished based on the glycosidic linkages 
present between the fructose residues and ITF are predominately linear molecules with β-
(2-1) fructosyl-fructose glycosidic bonds (163).  ITF can be extracted from plants (the 
predominant commercial inulin originates from chicory root) or synthesized from 
sucrose.  Inulin extracted from chicory root yields fructans with varying chain lengths; 
fructans range in degree of polymerization (DP) of 2-60 with an average of 12.  Chicory 
root fructans are generally a terminal glucose molecule linked to a fructose with “n” 
number of fructose units (“GFn  type”-see Figure 1-1) (24).    
 
     
Figure 1-1.  Basic GFn type fructan structure (163) 
Terminal glucose 
Repeating fructose units 
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Chicory-inulin extracts can undergo physical separation and/or enzymatic treatments to 
yield a variety of products (13, 24).   High molecular weight inulin can refer to physically 
purified inulin extracts that contain polysaccharides with a DP 10-60 and an average of 
25 (24).  Partial enzymatic hydrolysis of inulin can yield lower molecular weight 
versions, generally termed oligofructose (OF) with a DP 2-8 and an average of 4 (24).  
Enzymatic hydrolysis products of inulin can be composed of homopolymers of fructose 
with “m” number of fructose units (“Fm” type) or GFn (163).  ITF synthesized from 
sucrose are generally termed fructo-oligosaccharides (FOS) and have a DP 2-8 with an 
average of 3-6 (24).  ITF synthesized from sucrose can also be referred to as “neosugar” 
(2).   Sucrose derived FOSs are largely composed of a mixture of three oligosaccharides 
of the GFn type, i.e., 1-kestose (GF2), 1-nystose (GF3) and 1
F
-fructofuranosyl nystose 
(GF4) (164).  Because of the low molecular weight of the sucrose derived products, they 
are also frequently referred to as short-chain FOS or sc-FOS (164).  Since there is no 
official definition for ITF compounds, nomenclature is not consistent in the literature and 
some consider OF and FOS synonymous since both have a DP<10.  
 
Oligofructose and inulin are both highly soluble in water, although inulin is less soluble 
relative to oligofructose due to chain length.  Comparing a “standard” inulin (average DP 
of 12) to an enzymatic hydrolysis of inulin oligofructose (average DP of 4), the solubility 
of inulin was 120 g/L and oligofructose was >750 g/L (165).  Using a 5% w/w fiber in 
water solution, standard inulin had a viscosity of 1.6 mPa/s while oligofructose was <1.0 
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mPa/s (165).  Overall, both FOS and inulin are non-viscous, non-digestible (to humans) 
and do not contribute an objectionable flavor to food systems (163).  As mentioned 
previously, they are primarily obtained from chicory root but also occur naturally (in 
small amounts) in leeks, asparagus, Jerusalem artichoke, garlic, onion, wheat, banana and 
oats (164).  Inulin and shorter chain oligofructoses are well known to be highly 
fermentable at a variety of dosages in a variety of models: in vitro systems, animal 
models, and humans (14, 163, 166, 167) with this list representing a small sample of the 
studies performed.  As a whole, fructans generally do not affect stool weight, transit time, 
fecal SCFA/pH or fecal moisture.  Human studies have observed selective stimulation of 
bifidobacteria when consuming fructans, but increased incidence of gas and bloating is a 
common side effect.  Table 1-1 contains a summary of the effects of fructans on gut 
function and tolerance in human subjects. 
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Table 1-1. Effects of fructans on gut function and tolerance in human subjects. 
Fiber Stool weight Transit time or 
stool frequency 
Fecal short 
chain fatty acid 
Fecal pH  Fecal moisture 
or consistency 
Fecal bacteria Tolerance 
FOS, Inulin 
 
-DPav listed if 
reported 
 
-Excludes DPav 
>12 if defined  
No increase 
when 
supplemented to 
controlled diet  
 
-15 g/day inulin 
(DPav 10) and 15 
g/day FOS (DPav 
2-6) (168) 
 
-15g/day inulin 
and 15g/day FOS 
(169) 
 
-20g/day inulin, 
(DPav 9) (170)  
 
 
No difference in 
transit time 
compared to 
controlled diet  
 
-15 g/day inulin 
(DPav 10) and 15 
g/day FOS (DPav 
2-6) (168) 
 
-15g/day inulin 
and 15g/day FOS 
(169) 
 
-20g/day inulin, 
(DPav 9) (170) 
No difference in 
total SCFA 
compared to 
controlled diet 
 
-15g/day inulin 
and 15g/day FOS 
(169) 
 
-20g/day inulin 
(DPav 9) (170) 
 
-22-34 g/day 
inulin (DPav 9) 
(142) 
 
Difference in 
individual SCFA 
compared to 
control  
 
-20g/day inulin 
(DPav 9), higher 
acetate:propionat
e ratio (170) 
 
-15g/day inulin 
higher acetic acid 
(169) 
 
 
No difference 
compared to 
habitual diet 
 
-Controlled diets: 
15g/day inulin 
and 15g/day FOS 
(169) 
 
-Uncontrolled 
habitual diet: 20 
g/day FOS (143) 
 
 
No difference in 
fecal moisture 
compared to 
controlled diet  
 
-15 g/day inulin 
(DPav 10) and 15 
g/day FOS (DPav 
2-6) (168) 
 
No difference in 
total bacteria 
compared to 
habitual diet 
 
-Controlled diets: 
22-34 g/day 
inulin (DPav 9). 
FISH. 
(142) 
 
-15 g/day inulin 
(DPav 10) and 15 
g/day FOS (DPav 
2-6). Culture. 
(168) 
 
-Uncontrolled 
diet: 20 g/day 
FOS. Culture. 
(143) 
 
Increase in total 
anaerobes 
compared to 
controlled 
habitual diet 
 
-20g/day inulin 
(DPav 9). Culture. 
(170) 
Increased 
gastrointestinal 
symptoms 
compared to 
habitual diet 
 
-Controlled diets: 
Bloating and 
flatulence, 22-34 
g/day inulin 
(DPav 9) (142) 
 
Flatulence, 
20g/day inulin 
(DPav 9) (170) 
 
Flatulence and 
abdominal pain 
(12.5% 
participants 
report)  
flatulence and 
abdominal pain 
15 g/day FOS 
(DPav 2-6) (168) 
 
-Uncontrolled 
diets: 
  
Increased 
flatulence 20 
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Differences in 
groups of 
bacteria 
 
-1.2 log10 
increase in 
bifidobacteria,  
22-34 g/day 
inulin (DPav 9). 
FISH. 
(142) 
  
-Increased 
lactobacilli, no 
differences in 
bifidobacteria, 
clostridia, 
Enterobactericae
a, 20g/day inulin 
(DPav 9). Culture. 
(170)  
 
-Increased 
bifidobacteria at 
5, 10, 20 g/day 
FOS. Culture. 
(143) 
 
-Increased   
bifidobacteria 
and decreased 
Bacteroides, 
clostridia and 
fusobacteria 15 
g/day FOS (DPav 
2-6) (168)  
g/day FOS (143) 
  
Increased 
gastrointestinal 
discomfort 
during 7.8 g/day 
inulin period (no 
increase with 5 g) 
(171) 
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Gum acacia  
Gum acacia, or gum Arabic, is the “dried exudation obtained from the stems of A. 
Senegal (L.) Willdenow or closely related species of Acacia (family Leguminosae)” 
(172).  The gummy exudate is a highly heterogeneous material containing complex 
branched-chain polysaccharides found as a mixed calcium, magnesium and potassium 
salt of arabic acid with small amounts of protein  (173, 174).  Using hydrophobic affinity 
chromatography, gum acacia has been separated into three major fractions:   88.4% 
arabinogalactan (AG) with a low protein content (0.35%) and a molecular mass of 3.8 x 
10
5
 Da; 10.4% arabinogalactan-protein complex (AGP) containing 11.8% protein and 
molecular mass of 1.45 x 10
6
 Da; and 1.2% as a low molecular weight glycoprotein and a 
molecular mass of 2.5 x 10
5
 Da (175).  In general, the polysaccharide backbone is 
composed of 1,3-linked β-D-galactopyranosyl units with branches of similar 
galactopyranose units linked to the main chain via 1,6 linkages.  Refer to Figure 1-2 for 
the generic polysaccharide structure of the arabinogalactan portion. 
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Figure 1-2.  Generic polysaccharide structure of arabinogalactan portion of gum acacia 
(176)  
 
Both the main and side chains contain arabinopyranose, arabinofuranose and 
rhamnopyranose with glucuronic acid and 4-O-methylglucuronic acids as terminating 
groups (173, 175).  Based on photon correlation spectroscopy, it is thought that the 
majority of the gum has a highly branched, block-type structure which may explain why 
very high concentrations (>40%) of the gum are required before aqueous solutions 
become viscous (175).  Refer to Figure 1-3 for the proposed arabinogalactan-protein 
fraction of gum acacia exhibiting the highly branched, complex structure.   
 
 
 
Figure 1-3.  Proposed arabinogalactan-protein fraction of gum acacia.  Adapted from 
(177)  
 
Depending on the variety, age, and environment the trees are grown in, the chemical 
composition of gum acacia can vary (173).   
Compact arabinogalactan portion 
Protein portion 
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Gum acacia is highly soluble in water (1 g dissolves in 2 ml water) and is well fermented.  
Using a human fecal slurry in vitro system, approximately 95% of the gum acacia was 
fermented as measured by short chain fatty acid analysis and substrate disappearance 
(178, 179).  Fermentability of gum acacia has also been shown in vivo via stool output, 
SCFA analysis, fecal microflora, and breath hydrogen tests (178, 180).  Although data is 
limited in human studies, gum acacia shows promise in increasing stool weight and fecal 
moisture.  No differences in transit time have been observed.  Gum acacia is well 
tolerated up to doses of 40 g/day and some studies have observed increases in fecal 
bifidobacteria and lactobacilli.  Table 1-2 summarizes the effects of gum acacia on gut 
function and tolerance in human subjects. 
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Table 1-2.  Effects of gum acacia on gut function and tolerance in human subjects. 
Fiber Stool weight Transit time or 
stool frequency 
Fecal short 
chain fatty acid 
Fecal pH  Fecal moisture 
or consistency 
Fecal bacteria Tolerance 
Gum acacia Increased stool 
weight compared 
to semi-
controlled diet  
 
-15 g/day gum 
acacia (178) 
No change in 
stool frequency 
compared to 
habitual diet  
 
-Semi-controlled 
diet, 15 g/day 
gum acacia (178) 
 
-Uncontrolled 
diet, up to 40 
g/day gum acacia 
(181) 
 
No human data 
 
In vitro 
-Slowly, but 
extensively 
fermented.  Less 
than 2% 
constituent 
sugars remain 
after 48 h 
fermentation 
(179)  
No difference 
compared to 
semi-controlled 
diet 
 
 -15 g/day gum 
acacia (178) 
Increased fecal 
moisture 
compared to 
semi-controlled 
diet 
 
-15 g/day gum 
acacia (178) 
Differences in 
groups of 
bacteria 
 
-Semi-controlled 
diet, increased 
bifidobacteria 
and lactic acid 
producing 
bacteria, 15 g/day 
gum acacia (178) 
 
-Uncontrolled 
diet, increased 
bifidobacteria 
and lactobacilli, 
optimal 10 g/day 
gum acacia.  
PCR. (181) 
No difference in 
GI symptoms 
compared to 
habitual diet  
 
-Uncontrolled 
diet, up to 40 
g/day gum acacia 
(181) 
 
-Semi-controlled 
diet, 15 g/day 
gum acacia (178) 
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Outer pea fiber 
Pea hull fiber or outer pea fiber is obtained from grinding the hulls of the field pea 
(Pisum sativum) (182, 183).  The resulting ‘high fiber flour’ contains approximately 90-
95% fiber (as determined by standard AOAC methods), 3-6% protein, 2% ash, and <2% 
lipids, starch and sugar (183, 184, 185).  The amounts of insoluble to soluble fiber vary 
depending on particle size distribution and heat treatment, but have been approximated at 
87% insoluble and 4% soluble in raw pea hulls that have an average size of 500 um 
(184).  As particle size decreased and with extrusion conditions, the soluble fraction 
peaked at 15% soluble fiber (184).  Pea hulls are primarily composed of cellulose, along 
with xylose and arabinose-containing polymers and pectic substances (184, 186).  The 
insoluble fraction contains primarily cellulose (80%), xylose (10%), and arabinose (3%) 
and the soluble fraction primarily uronic acids (77%) i.e. pectin (186). The structure of 
the primary component cellulose is β (1, 4) linked glucose units.   Refer to Figure 1-4 for 
generic cellulose and pectin structures.  Cellulose and pectin are represented since they 
are found in the highest concentrations in the insoluble and soluble fractions of outer pea 
hull fiber. 
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Figure 1-4.  Generic structures of cellulose (left) and pectin (right) found in outer pea hull 
fiber.  (9) 
 
Pea hull fiber is a complex mixture of insoluble and soluble fibers.  As a whole, 
approximately 77% of a pea fiber was remaining after a 48 hour fermentation and 
produced a total of ~1240 µmol SCFA/g of substrate as opposed to a highly fermented 
substrate gum acacia ~9400 µmol SCFA/g in an in vitro system utilizing human fecal 
slurries (179).  These results were also corroborated in a pig model where both cellulose 
and xylose portions of the pea fiber had a high resistance to fermentation whereas the 
pectic portion was readily fermentable as measured by substrate recovery in the feces and 
SCFA analysis (7).   Since a large portion of pea hull fiber is cellulose, other properties 
such as water binding capacity/hydration may be of importance.  In a manuscript 
comparing relative hydration properties, pea hull fiber (particle size unknown) had a 
water binding capacity of 5.2 g water/g dry solids (185) with others reporting 6.6 g 
water/g dry weight (178) relative to cellulose 4.8 g water/g dry weight and wheat fiber 
4.4 g water/g dry weight (185).  Another study using similar water binding capacity 
measurements found that pea hulls of 500 µm average size had a binding capacity of 7.1 
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ml water/g dry weight vs. pea hulls of 80 µm average size had a binding capacity of 4.6 
ml water/g dry weight (184).  The authors suggest that the smaller particles led to a 
decreased water binding capacity due to the collapse of the fiber matrix.  As far as 
particulate viscosity, using 8% wt/vol of fiber and water, the viscosity of pea hull fiber 
was 3.63 mPa/sec at a shear rate of 122/sec while cellulose was 3.65 and wheat fiber 1.54 
(particle size not reported) (185).   
 
Data from outer pea hull fiber human feeding studies is extremely limited.  From the few 
studies performed, pea hull fiber shows promise in increasing stool weight, but no effects 
were seen on transit time.  Refer to Table 1-3 for a summary of the effects of pea hull 
fiber on gut function and tolerance in human subjects.
  50 
Table 1-3.  Effects of outer pea hull fiber on gut function and tolerance in human subjects. 
Fiber Stool weight Transit time or 
stool frequency 
Fecal short 
chain fatty acid 
Fecal pH  Fecal moisture 
or consistency 
Fecal bacteria Tolerance 
Pea hull fiber Increased stool 
weight compared 
to habitual diet  
 
-30g/day pea hull 
fiber (187) 
No difference in 
transit time 
compared to 
habitual diet  
 
-30g/day pea hull 
fiber (187) 
 
No change in 
colonic motility 
by high 
amplitude 
propagated 
contractions  
 
-15 g/day pea 
fiber (188) 
 
Increased bowel 
frequency in 
elderly residents 
compared to 
habitual diet  
 
-4 g/day pea fiber 
in 16 g total 
(182) 
No human data 
 
In vitro 
-Poorly 
fermented, 77% 
of fiber 
remaining after 
48 h fermentation 
(179) 
 
-Slowly and 
poorly 
fermented, 2% 
utilized after 6 h, 
and 22% at 24 
(187) 
 
No human data  
 
Based on poor 
fermentability 
would not expect 
acid to change. 
No human data 
 
Higher water 
binding capacity 
than wheat bran 
(6.6. g water/g 
dry weight vs. 
3.8) (187) 
No human data 
 
Based on poor 
fermentability 
would not expect 
bacteria to 
change. 
No differences in 
diet acceptability 
compared to 
habitual diet 
 
 -4 g/day pea 
fiber in 16 g total 
(182) 
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Rationale for a Fiber Blend 
Dietary fiber includes a wide variety of compounds and based on physicochemical 
properties, each provides a different physiological effect.  By supplementing enteral 
nutrition with a blend of fibers, the resulting fiber profile more closely resembles the 
mixed fibers supplied from a normal diet (81).  Additionally, by utilizing a fiber blend 
that contains both insoluble and well fermented soluble fibers, the beneficial effects 
associated with fecal bulking and fiber fermentation will theoretically be achieved 
(49).  Soluble fibers with known prebiotic properties provide additional benefits by 
stimulating the growth of health promoting bacteria.  Although some well fermented 
fibers cause gas and bloating in individuals, the use of a blend of fibers with a range 
of complexity (and thus speed of fermentation), may attenuate this.  Finally, by 
incorporating fibers with varying fermentation profiles, the health benefits associated 
with fermentation (such as short chain fatty acid production) will theoretically be 
prolonged throughout the large intestine. 
 
Inulin and fructo-oligosaccharides are well fermented, non-viscous, soluble fibers.  
Gas and bloating, however, are common side effects of fructan consumption in doses 
above 5-8 g (171).  As a prebiotic, fructans are the most well researched fibers.  Not 
as well studied, but showing promise as a prebiotic is gum acacia.  Gum acacia is 
fermented more slowly than FOS and inulin and when blended with FOS has been 
shown to increase the tolerance compared to inulin alone (189).  As a gum, acacia is 
unique since it is non-viscous in solutions up to 40% (9, 175).  Outer pea hull fiber 
provides insoluble fiber that has in vitro water binding capabilities greater than that of 
wheat bran, the gold standard in fecal bulking (187).  Additionally, it provides 
insoluble fiber without adding color, flavor, gluten, or soy to the product.   
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The novel fiber blend contains a 50:50 ratio of insoluble:soluble fiber containing pea 
hull fiber, inulin, fructo-oligosaccharides, and gum acacia. 
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CHAPTER TWO 
Healthy subjects experience bowel changes on enteral diets: addition of a fiber blend 
attenuates stool weight and gut bacteria decreases without changes in gas
1
 
 
Executive Summary 
Background: Tube-fed patients frequently suffer from abnormal bowel function 
which affects intestinal bacteria and quality of life.  Dietary fiber affects laxation and 
can be fermented by gut bacteria to produce metabolites which influence gut health 
and fecal moisture.   
Objective: The aim of this study was to compare the effects of a fiber blend fortified 
enteral formula (FB,15 g/L) and a fiber-free formula (FF), and habitual diet on bowel 
function, fecal bacteria and quality of life.   
Design: In a randomized, double-blind, crossover design, 20 healthy subjects 
consumed both FF and FB for 14 d with a 4-wk washout.  A 5-day fecal collection 
was used to assess stool output, whole gut transit time (WGTT), total bacteria, 
bifidobacteria, lactobacilli, clostridia, and bacteroides.  Bacteria were quantified via 
fluorescence in-situ hybridization. Subject gastrointestinal quality of life index 
(GIQLI) and side effects were also measured.   
Results: On formula diets, 5-day fecal output decreased by more than 55% from 
habitual diet, but was 38% higher on FB than FF (p=0.0321). WGTT was 
approximately 1.5 times longer on formula diets than habitual diet (p<0.0004).  Total 
bacteria declined from habitual diet on FF (p<0.004), but not on FB. Numbers of 
bifidobacteria and lactobacilli declined from habitual diet on both formula diets, but 
bifidobacteria was higher on FB compared to FF (p<0.0001).  Bacteroides and 
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clostridia numbers did not change between diets.  GIQLI and incidence of gas 
symptoms did not differ between formulas.   
Conclusions: Addition of a fiber blend moderated decreases in stool weight and gut 
bacteria observed in healthy subjects consuming FF.  These results support adding 
mixed fiber sources to enteral nutrition products if no contraindication exists.   
 
Introduction  
Enteral nutrition (EN), or enteral tube feeding, is an effective means of nutritional 
support for patients who do not or cannot eat adequately for a variety of medical 
reasons (39).   Administered in both hospital and home settings, EN use is frequently 
associated with gastrointestinal (GI) symptoms including diarrhea and constipation 
(29, 39).  EN associated GI intolerance affects patient quality of life and is a complex 
phenomenon affected by situation (drug therapies, concurrent infections, etc.), but the 
colonic bacteria are also involved (29, 190). Gut bacteria are involved in bowel health 
as a normal flora provides competitive exclusion for potentially pathogenic organisms 
(e.g. C.difficile) and ferments carbohydrates and proteins reaching the colon to 
produce short chain fatty acids (SCFA) (17, 47).  SCFAs affect colonic water 
absorption and decrease fecal pH which affects bacterial growth in the colon (45, 56).  
Disruption of gut bacteria homeostasis (dysbiosis) is thought to contribute to many 
bowel ailments and previous studies have shown changes in gut bacteria while on 
enteral nutrition (48, 129, 190, 191).  
A wide range of compounds are considered dietary fiber, and depending on 
physiochemical properties, have different physiological effects.  Some fibers increase 
fecal bulk and/or hold water which facilitates colonic motor activity and promotes 
normal laxation (10).  Others are fermented in the distal colon to produce SCFAs 
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which through their effects on colonic fluid absorption, may prevent or ameliorate 
diarrhea-like symptoms (45).  By using a blend of fibers to fortify EN, the 
physiological effects of fiber such as bowel function moderation, SCFA production 
and healthy gut microbiota maintenance are maximized (192).  Blends may also be 
used to minimize the contraindications of gas and bloating (192).  Furthermore, 
adding fibers that selectively stimulate the growth and activity of bacteria which 
improve host health (“prebiotics”) may help to attenuate the growth of potentially 
harmful bacteria (14).  Most prebiotic studies have focused on increases in 
bifidobacteria (144).    
 
The aim of this study was to compare the effects of a fiber blend fortified enteral 
formula (FB), a fiber-free formula (FF) and habitual diet on bowel function, fecal 
bacteria and quality of life in healthy subjects.  The primary objective of the trial was 
to compare the stool weight of the subjects consuming these diets.  The secondary 
objectives were to evaluate the effects of the diets on modification of the major 
groups of gut bacteria, whole-gut transit time (WGTT), Bristol stool form, fecal 
moisture, fecal pH and subjective tolerance.   
 
Subjects and Methods 
Subjects.  Healthy men and women were recruited on the University of Minnesota 
campus to a prospective, randomized, double-blind, crossover trial.  Exclusion criteria 
included: age <18 or >75, BMI <23 or >29,  any self-reported disease, use of 
medication (except contraception and certain over the counter medications), smoking, 
>2 h exercise per week, consumption of >20 g fiber/day, pregnancy or lactation, use 
of laxatives, use of antibiotics in the past 6 mo., use of pre or probiotic supplements in 
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the past 2 mo., use of probiotic foods in the past month, participation in another 
clinical trial during the last 4 weeks prior to the beginning of the study, and known 
allergy or sensitivity to formula ingredients. Subject eligibility was determined via 
questionnaire and an initial visit to obtain physical measurements.  Refer to Appendix 
B for the eligibility screening questionnaire.   Habitual diet daily fiber intake was 
screened via a fruit, vegetable, and fiber frequency questionnaire and measured using 
2 d diet records entered into Nutrition Data System for Research (University of 
Minnesota, Version 2011) (193).  A sample size calculation indicated that 20 subjects 
were required to detect a 21 g/day difference in fecal weight (80% power, 0.05 
significance) based on a previous enteral study (48).  Refer to Appendix A for the 
sample size/power calculation.  Written informed consent was obtained from each 
subject and the study was approved by the University of Minnesota Institutional 
Review Board for Human Research Protection Program and registered at 
clinicaltrials.gov.  The informed consent form is listed in Appendix C.   
 
Subject Protocol.  During the study, subjects were asked to maintain their normal 
activity level and refrain from any exclusion criteria behaviors (laxatives, 
prebiotic/probiotic foods, etc.).  Approved over the counter medication was recorded 
in subject records.  Subjects consecutively completed a run-in period of 14 days on 
habitual diet, 14 days on enteral formula diet 1, 28 days on habitual diet (washout 
phase), and enteral formula diet 2 for 14 days.  Enteral formula diets were assigned in 
random order and the two treatment sequences (FF-FB or FB-FF) were given in equal 
numbers, stratified by gender.  See Appendix F for the randomization schedule.  
Enteral formula was orally consumed as the sole source of nutrition with no other 
dietary intake except ad libitum consumption of water and coffee, tea and non-
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caloric/no-fiber containing beverages in similar amounts consumed during habitual 
diet.   
 
Subject weight was recorded at the start and end of each period.  Gastrointestinal 
quality of life was measured at the end of each period.  Subjects recorded 2 day diet 
records during habitual diet periods and 14 days during the enteral formula periods.  
A capsule containing 20 radioopaque pellets for the measurement of transit time was 
consumed on Day 8 of each period.  Subjects performed a 5-day total fecal collection 
the last five days of each period.  For the fecal sampling, individuals collected every 
stool produced during the collection period and recorded the date and time of each 
stool.  The last stool sample from each fecal collection was collected anaerobically by 
immediately placing it into a Bitran Speciman Storage Bag (Fisher Scientific, 
Pittsburgh PA) which contained an Anaeropack  Anaero (Mitsubishi Gas Chemical 
America, New York NY).  The anaerobically stored stool was placed on ice in an 
insulated cooler, delivered to the laboratory within 1 h of defecation, and processed 
immediately to maintain microbial viability and ensure standardized sample 
preparation and handling. 
 
Enteral formula.  Enteral formulas were nutritionally complete and identical in 
composition except for fiber content.  Base formula contained 1500 kcal/L, 67.6 g 
protein/L, 64.8 g fat/L and 168 g carbohydrate/L.  The fiber containing formula was 
the base formula supplemented with 15 g/L of fiber blend.  The fiber blend contained 
a 50:50 insoluble: soluble mixture of short-chain fructo-oligosaccharides and inulin 
(Beneo, Morris Plains NJ), pea hull fiber (Nutri-Pea Limited, Manitoba Canada), and 
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gum acacia (Nexira, Somerville NJ).  Refer to Appendix D for the complete nutrition 
information and ingredient list for the formulas.  
 
Subjects received amounts of enteral formula based on their total energy expenditure 
(TEE).  TEE was calculated using the Harris-Benedict equation for basal metabolic 
rate and adjusting with physical activity factors (194).  Formula was provided in 
identically labeled 250 ml cans with the exception of product code.  Formulas were 
assigned four different codes to ensure that both subjects and researchers were 
unaware of the formula type.  All formula was vanilla flavored.  Subjects were 
provided with excess formula of their prescription and were withdrawn from the study 
if the intake was below 75% of the target volume for two consecutive days.  Formula 
consumption compliance was assessed via diet records, and subjects were not 
informed of the procedure to ensure accuracy.   
 
Fecal collection and stool sample preparation.  Five day fecal collections delivered 
to the lab were weighed, assessed for Bristol type and frozen at -20°C (91).  The 
anaerobically packaged stool was weighed, assessed for Bristol type, mixed, and 
diluted 1:10 in phosphate buffered saline (PBS, 0.1 M, pH 7.2) using a 10 g aliquot.  
The fecal:PBS mixture was homogenized in a stomacher for 2 min and the slurry was 
aliquoted for fecal bacteria measurements.  The remaining sample was frozen at -
80°C until subsequent testing. 
 
Mean transit time, stool frequency, and Bristol stool form.  Subjects consumed a 
single dose of 20 radioopaque (polythene) pellets placed into a size 00 food grade 
gelatin capsule and recorded the time consumed.  Subsequent stool samples were then 
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collected for 5 days.  The stool samples produced were x-rayed to determine pellet 
content.  Mean transit time was calculated as the sum of the product of the number of 
pellets in a stool and the time of excretion (of that stool) which was divided by the 
total number of pellets recovered (as determined by x-ray) (82).  Stool frequency was 
the number of stools produced per 5 day collection period.  Stool form was visually 
determined by comparison to the Bristol scale pictorial and verbal descriptors.  The 
Bristol scale includes seven types of formed-ness ranging from 1 (most formed-
separate hard lumps) to 7 (least formed-watery, no solid pieces) (91).  See Appendix G 
for the Bristol stool chart. 
 
Fecal moisture.  Anaerobically collected fecal samples were thawed and re-mixed.  
Aliquots of 2-5 g were measured in triplicate and spread into a thin layer in pre-dried 
(24 h at 105°C) and pre-weighed 64 mm diameter aluminum pans.  Prepared stool 
samples were placed in a 105°C for 24-48 h, removed and cooled under desiccant.  
Stool weight loss was recorded and used to determine moisture content (98, 195). 
 
Enumeration of fecal bacterial populations by fluorescence in situ hybridization.  
Fecal sample preparation and fixation was performed as described by Costabile (121).  
Triplicate 375 µL aliquots of the 1:10 fecal slurry were added to 1125 µL of 4% 
paraformaldehyde (w/v, pH 7.2) and fixed at 4°C for 4-8 h.  Samples were washed 
with 0.2 µm filtered PBS (twice), re-suspended in 300 µL of 1:1 (v/v) PBS:ethanol 
mixture, and stored at -80°C until analysis.  
 
Hybridization was performed using conditions outlined in probeBase and as described 
by Martin-Pelaez (196, 197). Probes were used to target total bacteria (EUB338 5’-
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GCT GCC TCC CGT AGG AGT-3’) (198), bifidobacteria (BIF164 5’-CAT CCG 
GCA TTA CCA CCC-3’) (199), lactobacilli-enterococci (LAB158 5’-GGT ATT 
AGC AYC TGT TTC CA-3’ (200), bacteroides (BAC303 5’-CCA ATG TGG GGG 
ACC TT-3’ (201) and the Clostridium coccoides-Eubacterium rectale group 
(EREC482 5’-GCT TCT TAG TCA RGT ACC G-3’ (202).  All probes were cyanine-
3 (Cy-3) labeled and synthesized by Sigma Aldrich.  Fixed fecal samples were thawed 
on ice, and 20 µL of appropriately diluted sample was pipetted onto Teflon and poly-
L-lysine-coated, six-well (10 mm diameter each) slides (Tekdon Inc., Myakka City, 
FL USA).  For lactobacilli analysis, slides were treated with 50 µL of lysozyme (2 
mg/ml in 1mM Tris/HCl) at 37°C for 30 min and rinsed with water after drying to 
permeabilize cells.  All samples were dehydrated in a series of ethanol concentrations 
for 3 min each (50%, 80%, 96%).  A probe/hybridization buffer mixture (5 ng/µL) 
was applied to each well and the hybridization was performed in a sealed, humidified 
chamber for 4 h.  Slides were washed in 50 ml of wash buffer containing 50 ng/µL of 
4,6-diamidino-2-phenylindole dihydrochloride (DAPI) for 15 min, and then 2-3 s in 
ice-cold water.  Slides were dried using compressed air.  Five µL of polyvinyl alcohol 
mounting medium with 1,4-diazabicyclo(2-2-2)octane antifade was added to each 
well.  Slides were stored at 4°C in the dark for a maximum of 3 days until being 
counted.   
 
Slides were evaluated using a Nikon E800 Hyperspectral microscope equipped with a 
XCite mercury lamp and a Photometrics HQ2 charge-coupled device camera.  The 
Cy-3 labeled probe and DAPI stained slides were visualized using a filter cube; 
excitation filter 555-585 nm and emission filter 590-650 nm (Cy-3) and excitation 
filter 385-415 nm and emission filter 450-470 nm (DAPI).  Bacterial populations were 
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quantified as in Martin-Pelaez (196).  Total bacteria were counted using digitally 
captured images.  All other groups of bacteria were counted without imaging.   
 
Gastrointestinal symptoms and quality of life.  Gastrointestinal quality of life index 
(GIQLI) was measured using a validated 36 question questionnaire that measures 
physical well-being, mental well-being, digestion and defecation (132).  The GIQLI 
also addresses general gastrointestinal symptoms such as diarrhea, constipation, 
abdominal pain and nausea.  For each question the most desirable option is 4 points 
with the least desirable option assigned a 0.  The GIQLI is the overall sum of the 
points with a maximum score of 144.  To calculate separate scores for gas/bloating, 
constipation, and bowel urgency, scores of questions relating to those areas were 
summed separately.  Refer to Appendix E for the complete GIQLI. 
 
Statistical analysis 
The two sequence groups (FB-FF vs FF-FB), dietary fiber and demographic 
characteristics were compared by ANOVA.  Responses to the treatments and habitual 
diet were compared by linear contrasts in mixed-effects linear models, where period 
(1-4), gender and treatment were fixed effects and subject (intercept) was a random 
effect to model the within-subject correlation for repeated measurements.  The 
assumptions of equal carryover and no period-treatment interaction were tested for 
each outcome.  Analysis of bacterial counts was done and reported on the log10 scale.  
Data collected during the initial habitual diet and washout periods were combined and 
adjusted for period effects and used to report habitual diet values.  Data analysis was 
performed in SAS (Version 9.2) and differences were considered significant at P < 
0.05.  
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Results 
Cohort.  Twenty-four healthy subjects were enrolled in the study.  Twenty subjects 
(10 men, 10 women) completed the study and 4 dropped out (2 men, 2 women) within 
the first 2 days of the first liquid diet and did not complete the GIQLI for the liquid 
diet.   One man dropped because he was unable to consume enteral formula as a sole 
source of nutrition and another because he found his breath to be malodorous when on 
the formula.  One woman dropped due to dislike of the formula and another was 
unable to fully comply with study procedures.   
 
We report results only for the 20 who completed the study.  Subject baseline 
demographic characteristics and diet information are listed in Table 2-1.  Baseline 
characteristics of the two sequence groups were compared, and no statistical 
differences were found.  
 
Enteral formula intake and compliance. Enteral formula prescription was based on 
individual energy needs and actual intake was calculated from subject diet records 
during the formula periods.  Subjects were considered to be compliant if they 
consumed at least 75% of their energy needs, and did not consume below 75% for 2 
consecutive days.  All subjects who completed the study were compliant.  There was 
no overall difference in reported formula intake between fiber-free or fiber blend 
containing formula. Table 2-1 lists the total and gender specific formula energy and 
fiber intake.  Most subjects lost weight during each 14 day enteral formula period.  
There was no difference in weight loss between subjects consuming fiber free formula 
(1.2 kg +/- 0.3 SE) and fiber blend formula (1.7 kg +/- 0.3 SE, p = 0.21). 
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Fecal output and characteristics.  Subjects on FB had a 38% higher mean 5-day 
fecal output compared to FF (p=0.0321, Table 2-2).  Compared to habitual diet, mean 
5-day fecal output was reduced by 55% on FB and by 67% on FF (both p<0.0001).  
Gender was a significant predictor for stool weight and values reported are gender 
adjusted.  Whole gut mean transit time was approximately 1.5 times longer during 
formula diets compared to habitual diet (both p<0.001, Table 2-2), but was not 
significantly different between the formulas (p=0.2570).  Stool frequency (stools/5 d) 
was higher on habitual diet than the formula diets (both p<0.001) and there was no 
difference between formulas.  Fecal moisture values were 4% (wet basis) higher on 
FF than both habitual diet and FB (both p<0.0001, Table 2-2), which did not differ.  
Mean Bristol stool scores indicated that the stools produced on FF were least formed, 
intermediate on FB and most formed on habitual diet (all p<0.0001).     
 
Overall gastrointestinal quality of life scores for subjects consuming formula diets 
were the same between formulas (p=0.8573), but lower during habitual diet (both 
p<0.001, Table 2-3).  Incidence of constipation and gas/bloating symptoms were not 
different between formulas or between either formula and habitual diet.  Incidence of 
symptoms related to increased bowel urgency/uncontrolled stool was lowest on 
habitual diet, intermediate on FB, and highest on FF (all p<0.02).    
 
Total bacteria declined from habitual diet on FF but not on FB (Table 2-4). Numbers 
of bifidobacteria and lactobacilli declined on both FF and FB, and the decline was 
significantly greater in FF.  Numbers of bacteroides did not change, but there was a 
trend toward increased numbers of clostridia on FF vs. habitual diet (p=0.0528). 
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Finally, mean fecal pH for both formulas was 7.5; higher than habitual diet pH 6.5 
(p<0.0001, Table 2-4).  
 
Discussion  
Subjects on FB had increased 5-day stool weight (total fecal output) compared to FF 
even though FF had higher moisture content.  Whelan et al measured similar increases 
in fecal weight in healthy subjects consuming standard and fiber fortified enteral 
formula (48).  Both formulas, however, reduced stool weight to less than 50% of 
habitual diet levels despite receiving a mean fiber dose of 18.9 g/day on FB formula 
and 16.0 g/day on habitual diet.   While fecal weight is affected by fiber intake, the 
water the fiber binds, fecal microbe weight, and short-chain fatty acid concentration, 
other factors such as personality have also been associated with fecal output (49, 58, 
59).  Fecal output reductions occurring when consuming standard and/or fiber 
containing enteral formula compared to habitual diet have also been documented in 
other studies (48, 79, 81).  Slavin et al observed that 60 g/day of soy fiber added to 
enteral nutrition was necessary to increase stool weight to self-selected diet levels 
(79).  Additional factors contributing to the marked decrease in stool weight 
compared to habitual diet may be decreased particle size of the isolated fibers (10), 
naturally occurring FOS and resistant starch not measured by typical fiber analytical 
methods (203), and fiber type/proportions in the blend (different fibers affect fecal 
weight differently) (58).  
 
Whole gut transit time influences water and SCFA absorption from stool and previous 
human feeding studies have observed inverse correlations with stool weight and 
transit time (61).  In general, the longer feces remain in the large intestine, the more 
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water is absorbed which may lead to a highly formed stool (49, 197).  In this study, 
mean transit time was approximately 1.5 times longer for subjects consuming formula 
diets compared to habitual diets.  Silk et al observed significantly longer WGTT on 
fiber free formula than habitual, but saw no difference between habitual and fiber 
containing formula.  Fiber doses on that fiber containing formula, however, averaged 
30 g/day (87).  
 
Fecal moisture values were higher on FF compared to FB possibly due to decreased 
fermentation and SCFA production by the gut bacteria.  SCFA increase sodium and 
water uptake in the colon and may lead to a decreased moisture content (as seen in the 
fiber blend formula) (45, 111).  Moisture values were similar for FB and habitual diet.  
Bristol stool formed-ness followed similar trends as fecal moisture; habitual diet and 
FB were more normally formed while FF was less formed and trended toward 
diarrhea.  FF had the highest moisture content and least formed stool which is 
consistent that individuals restricted to fiber free enteral nutrition have more frequent 
diarrhea (29, 44). Furthermore, Bowling et al demonstrated that high energy density 
enteral nutrition causes net secretion in the distal colon (204). 
 
Overall GIQLI was decreased from habitual diet on both formula diets, which wasn’t 
surprising due to the high level of dietary restriction and social impact of being on a 
liquid diet.  Wierdsma et al also observed decreased GIQLI for patients on enteral 
nutrition versus healthy controls (129). GIQLI was not different between formulas in 
this study, although Wierdsma found that patients receiving fiber free formula had 
decreased GIQLI versus fiber containing formula (129).  
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Symptoms related to constipation and gas/bloating did not differ between any diets.  
Similar results were observed by Whelan et al that found no differences between 
nausea, bloating and flatulence for habitual, fiber free or fiber containing formula 
(48).  Since no increases in gas/bloating incidence where found, it suggests that the 
constituents of the fiber blend are fermented in a manner that is well tolerated in 
individuals.  Greater gas volume is perceived more in the proximal bowel compared 
to the distal colon, so rapidly fermented fibers would be expected to cause more 
gastrointestinal intolerance than those that are more slowly fermented (205).  Using a 
blend of fibers with various chain lengths may attenuate gas production and this has 
been demonstrated in previous in vitro studies (128, 206).  
 
Formula diets appear to increase the incidence symptoms of bowel urgency, although 
the FB had less than the FF.  Symptoms related to bowel urgency were highest on FF, 
intermediate on FB and lowest on habitual.  This is in agreement with other studies 
that suggest individuals on enteral nutrition frequently have abnormal bowel function 
such as diarrhea (29, 44, 204).  Although diarrhea is not well defined in the literature, 
urgent bowel movements are typically correlated with diarrhea. 
 
Numbers of total bacteria where significantly reduced in individuals consuming FF 
compared to habitual diet which may be due to decreased substrates for bacterial 
metabolism and has also been measured in a similar enteral nutrition study (48).  
Between formulas, the numbers of bacteria were higher on FB (although not 
significant), and other studies have observed more bacteria in individuals consuming 
fiber formula (48, 123).    
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The most marked changes in bacterial populations were observed in the 
bifidobacteria.  Compared to habitual diet, bifidobacteria were reduced by 2 log10 
when consuming FF but were partially restored (increased) when consuming FB. 
Again, prebiotics, such as FOS and inulin are known to selectively stimulate the 
growth of bifidobacteria (14), and other enteral studies have observed decreases in 
bifidobacteria on fiber free formula (48, 129).  Although prebiotics are also suggested 
to increase lactobacilli levels, this study found no differences in populations between 
the formulas and a reduction in numbers from habitual diet.  Clostridia increased from 
habitual diet when on FF, but the changes were not significant and no other 
differences were measured.  Bacteroides populations were not different among any 
treatments and this was also observed by Whelan et al (48).  
 
Finally, pH was higher on both formula diets vs. habitual diet. This was not surprising 
since total bacterial populations (and thus fermentation) were decreased on formula, 
but it was hypothesized that the fiber blend would have a somewhat decreased pH 
compared to fiber free as seen in other studies (48). 
 
Conclusions 
Significant bowel function changes occur when healthy subjects transition to an 
exclusive enteral diet.  Subjects consuming a formula supplemented with a fiber 
blend, however, had increased fecal weight, a moderately formed stool and less 
negative symptoms related to bowel urgency/uncontrolled stool without a difference 
in gas/bloating symptoms compared to fiber-free formula.  Overall GIQLI was not 
different between the test formulas.  These results support the addition of mixed fiber 
sources to enteral products. 
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Table 2-1.  Subject baseline demographics and diet characteristics of 20 subjects 
consuming fiber free formula, fiber blend formula, and habitual diet. 
 Age  
(y) 
Body 
Mass 
Index 
(kg/m
2
) 
Habitual 
Diet 
Energy 
Intake
1
 
(kcal/d) 
Formula 
Diets 
Energy 
Intake
2
 
(kcal/d) 
Habitual 
Diet 
Fiber 
Intake
1
 
(g/d) 
Formula 
Diet 
Fiber 
Intake
2
 
(g/d) 
Women  
(n=10) 
25.7 
(12.4) 
25.3 
(2.8) 
1914 
(580)
a
 
1615 
(204) 
16.8 
(4.2) 
16.2 
(1.9)
b
 
Men 
(n=10) 
25.8 
(7.3) 
26.2 
(2.3) 
2223 
(599) 
2225 
(347)
c
 
15.1 
(6.5) 
21.6 
(3.8)
d
 
Total 
(n=20) 
25.8 
(9.9) 
25.8 
(2.5) 
2069 
(594) 
1928 
(417) 
16.0 
(5.3) 
18.9 
(4.0) 
Values are means (standard deviation) 
1
Habitual diet energy and fiber intake are reported as an average of the 2 day diet 
records from the baseline and washout periods.  Values were generated using the 
Nutrition Data System for Research (Version 2011). 
2
Formula diet energy intake is reported as an average of the 14 day diet records 
combined over FF and FB.  Formula fiber intake is reported as an average of the 14 
day diet records from FB. 
a
In women, energy intake on habitual diet is different from formula diet (p=0.009). 
b
Fiber intake on formula diet is different between men and women (p=0.0009). 
c
Energy intake on formula diets is different between men and women (p<0.0001). 
d
In men, fiber intake on habitual diet is different from formula diet (p=0.0153). 
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Table 2-2.  Fecal output, stool characteristics and mean transit time of 20 subjects 
consuming fiber free formula, fiber blend formula, and habitual diet. 
 Habitual diet Fiber free 
formula 
Fiber blend 
formula 
Fecal output
1
 
(g/5 d) 
825 (56)
a
 267 (33)
b
 368  (33)
c
 
Mean transit 
time 
(h) 
59 (7)
a
 101 (10)
b
 
n=19 
87 (10)
b
 
n=19 
Stool frequency 
(n stools/5 d) 
5.3 (0.3)
a
 3.9 (0.3)
b
 3.7 (0.3)
b
 
Fecal Moisture 
(% wet basis) 
74.5 (0.9)
a
 78.3 (1.4)
b
 73.6 (1.4)
a
 
Bristol stool 
score
2
 
3.2 (0.2)
a
 5.1 (0.3)
b
 4.2 (0.3)
c
 
Values are means (standard error).  Groups were compared in each row.  Means with 
no letters in common were significantly different (p < 0.05); means sharing a letter 
were not significantly different. 
1
Fecal output values were adjusted for gender. 
2
Bristol scores range from 1 (most formed, separate hard lumps) to 7 (least formed, 
watery no solid pieces). 
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Table 2-3.  Gastrointestinal quality of life index (GIQLI) and incidence of 
gastrointestinal symptoms of 20 subjects consuming fiber free formula, fiber blend 
formula and habitual diet.   
 Habitual diet Fiber free 
formula 
Fiber blend 
formula 
GIQLI
1
 129.9 (1.9)
a
 123.5 (2.4)
b
 123.2 (2.4)
b
 
Gas-bloat score
1
 17.3 (0.4)
a
 17.3 (0.4)
a
 18.0 (0.4)
a
 
Bowel urgency 
score
1
 
15.5 (0.3)
a
 13.1. (0.6)
b
 14.4 (0.6)
c
 
Constipation 
score
1
 
3.8 (0.1)
a
 3.7 (0.1)
a
 3.6 (0.1)
a
 
Values are means (standard error). Groups were compared in each row.  Means with 
no letters in common were significantly different (p < 0.05); means sharing a letter 
were not significantly different.  
1
Higher scores indicate more favorable outcomes; symptoms with lower scores occur 
at a higher incidence. 
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Table 2-4.  Log10 fecal bacteria populations and pH of 20 subjects consuming fiber 
free formula, fiber blend formula and habitual diet. 
 Habitual diet Fiber free 
formula 
Fiber blend 
formula 
Total bacteria
1
 11.58 (0.08)
a
 11.28 (0.10)
b 
n=19 
11.38 (0.10)
ab 
n=19 
Bifidobacteria
1
 7.29 (0.16)
a
 5.07 (0.19)
b
 6.87 (0.19)
c
 
Lactobacilli
1
 6.49 (0.12)
a 
n=19 
6.10 (0.15)
b 
n=18 
6.11 (0.15)
b 
n=18 
Clostridia
1
 8.36 (0.06)
a
 8.52 (0.07)
a
 8.42 (0.07)
a
 
Bacteroides
1
 8.51(0.06)
a
 8.40 (0.07)
a
 8.50 (0.07)
a
 
pH 6.52 (0.07)
a
 7.49 (0.09)
b
 7.54 (0.09)
b
 
1
log10 cells/g stool.   
Values are means (standard error). Groups were compared in each row.  Means with 
no letters in common were significantly different (p < 0.05); means sharing a letter 
were not significantly different. 
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CHAPTER THREE 
Coupling fermentation results from a 24 h batch in vitro system with fecal 
measurements and subjective tolerance from a human intervention feeding study 
using fructo-oligosaccharides, inulin, gum acacia and pea fiber
1
 
 
Executive Summary 
Fiber fermentation in the gut increases short chain fatty acid (SCFA) and gas 
production.  Patients receiving fiber-free enteral nutrition frequently suffer from 
abnormal bowel function and may benefit from the addition of fiber.  In vitro systems 
estimate fermentation and tolerance of fiber while human studies are the gold standard 
in nutrition. The objectives of this trial were to compare the in vitro fermentation 
profiles of fructo-oligosaccharides (FOS), inulin, gum acacia, and pea fiber alone or 
blended using a 24 h batch model and relate these findings to in vivo results.  The 
fiber blend was added to an enteral formula (15g/L) and fed to 20 healthy human 
subjects for 14 days in a randomized, crossover, double blind study with a 28 day 
washout.  Stool samples were collected during the human study to determine fecal 
acids while gas symptoms were assessed via questionnaire.  The in vitro fermentation 
of the fiber blend resulted in a delayed pH decrease and gas and SCFA production 
compared to the FOS and inulin.  Human samples had higher total SCFA on the fiber 
formula compared to the fiber free formula (p=0.029), and both formulas yielded 
lower SCFA than habitual diet (both p<0.0001). Mean fecal pH for both formulas was 
7.5; higher than habitual diet pH 6.5 (p<0.0001).  No differences in the frequency of 
gas and bloating were found between any diet.  By blending fibers, a slower 
fermentation was observed in vitro and was well tolerated in human subjects.  Fiber 
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addition to enteral formula increases fecal short chain fatty acids which may reflect 
increased fermentation.   
 
Introduction 
The human large intestine contains up to 10
12
 bacterial cells/g contents with over 400 
different species represented (55).  Gut bacteria ferment non-digestible carbohydrates 
to produce short chain fatty acids (SCFAs) and hydrogen, carbon dioxide, and 
methane gases.  Proteins may also be fermented if sufficient carbohydrates are not 
available, and this results in branched chain fatty acids and other products (56, 107).  
The major SCFAs in the colon are acetate, propionate and butyrate although branched 
chain fatty acids and other products are found in lesser amounts (56). Gas is a product 
of fermentation and large amounts produced in vivo may cause bloating and 
discomfort (128).   
 
SCFA are thought to be readily absorbed in a normal colon via both nonionic 
diffusion and ionic exchange and up to 95% of SCFA are thought to be absorbed from 
colonic contents (45, 109).   In total, SCFAs reduce fecal pH, stimulate electrolyte and 
colonic fluid absorption, provide energy to the host and may affect gut transit time 
(72, 111).  Individually, butyrate is the preferred form of fuel for colonocytes and 
plays a role in cell differentiation and proliferation (113).  Acetate and propionate are 
absorbed and utilized by the liver (although to different degrees) with acetate the 
major acid entering systemic circulation (115, 117). 
 
Diarrhea and selective bacterial overgrowth are common complications that occur 
with enteral nutrition (EN) (48, 123).  Besides increasing fiber intake, addition of 
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fiber to enteral formulas has been shown to decrease diarrhea and colonization of 
potentially pathogenic bacteria through the increased production of SCFAs and 
decreases in colonic pH (46).  By using a blend of fibers to fortify formula, the fiber 
profile more closely resembles a mixed diet (192).  Furthermore, by blending fibers 
with various physicochemical properties, a variety of physiological benefits may be 
achieved with minimal gas and bloating.  
 
Fecal SCFAs reflect the amount of SCFA left after microbial production and 
colonocyte absorption.  Batch in vitro systems allow fermentation modeling without 
absorption and may help to estimate potential health benefits and gastrointestinal 
tolerances of fibers in vivo (207).  Well controlled, blinded and randomized 
intervention human studies are the “gold standard” for human nutrition research. 
 
The objective of the in vitro study was to compare the fermentation profiles of 
different dietary fibers alone or blended using a 24 h batch system.  The fiber blend 
was then added to an enteral nutrition product and fed to human subjects.  The 
objective of the human study was to compare the effects of fiber-free enteral formula, 
a fiber blend-fortified formula and habitual diet on fecal acids and gas symptoms in 
healthy subjects.   
 
Methods and Materials 
In vitro fermentation using human fecal inoculums 
Potential human fecal sample donors were recruited on the University of Minnesota 
campus.  Subjects were screened using a questionnaire.  Inclusion criteria was self-
reported absence of disease (“healthy”), consumption of a non-specific western diet,  
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and no antibiotic use for three months prior to the study.  Fecal samples were 
collected using a Commode Specimen Collection System (Sage, IL, USA) lined with 
a 2 mm thickness plastic bag.  Samples were immediately placed into an anaerobic 
bag (Remel, Lenexa, KS) containing an AnaeroPouch anaerobic sachet (Mitsubishi 
Gas Company, Tokyo Japan), sealed with a Pouch Clip (Remel, Lenexa, KS) and 
placed on ice in an insulated container to maintain microbial viability and ensure 
standardized sample preparation.  Fecal samples were delivered to the laboratory and 
processed within 2 h. 
 
Fiber samples were provided by Nestle Health Science S.A. (Lutry, Switzerland) in 
coded pouches, and investigators were blinded to the treatments.  The fibers tested 
were fructo-oligosaccharides (FOS, Beneo, Morris Plains NJ), inulin (Beneo, Morris 
Plains NJ), gum acacia (Nexira, Somerville NJ), outer pea fiber (Nutri-Pea Limited, 
Manitoba Canada), and a 50:50 soluble: insoluble blend of FOS, inulin, gum acacia, 
and outer pea fiber.  Half a gram (0.5g) of each fiber or blend was weighed and placed 
into sterilized 100 mL serum bottles.  Forty mL of sterile trypticase peptone 
fermentation media was added to each bottle and fibers were allowed to hydrate for 
12 h at 4C (208).  The fiber:media slurry was heated to 37C and 10 mL fecal 
inoculum was added to each bottle along with 0.8 mL Oxyrase ® (Oxyrase Inc., 
Mansfiled, OH USA) to remove oxygen from the environment.  Fecal inoculum was 
prepared by pooling three fecal samples with phosphate buffer solution (1:6 w/v) and 
then mixing two parts reducing solution (950 mL of distilled water, 6.25 g of cysteine 
hydrochloride, 40 mL 1N sodium hydroxide, 6.25 g of sodium sulfide nonahydrate) to 
15 parts diluted fecal inoculum (v/v) (209).  Bottles were flushed with carbon dioxide 
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and sealed.  Sealed bottles were placed in a 37C shaking water bath and allowed to 
ferment for 0, 4, 8, 12, and 24 hours (triplicate bottles for each timepoint).   
 
In vitro pH, gas volume and SCFA 
At each timepoint, aliquots were taken for measurement of pH, gas volume and 
SCFAs.  Gas volume was measured by piercing the rubber cap of the sealed 
fermentation bottle with a 50 mL or 100 mL glass syringe fitted with a stainless steel 
needle and allowing the gas to fill the syringe (210). The pH of the fermented 
treatments was measured with a calibrated pH probe, and following pH measurement, 
1 mL of copper sulfate (200 g/L) was added into the serum bottles to inhibit further 
fermentation.  A two mL aliquot was removed from each triplicate for SCFA 
measurement and frozen at -20C until subsequent analysis. 
 
Enteral nutrition human feeding study 
Subjects. 
Healthy men and women were recruited on the University of Minnesota campus. 
Exclusion criteria included: age <18 or >75, BMI <23 or >29,  any self-reported 
disease, use of medication (except contraception and certain over the counter 
medications), smoking, >2 h exercise per week, consumption of >20 g fiber/day, 
pregnancy or lactation, use of laxatives, use of antibiotics in the past 6 mo., use of pre 
or probiotic supplements in the past 2 mo., use of probiotic foods in the past month, 
participation in another clinical trial during the last 4 weeks prior to the beginning of 
the study, and known allergy or sensitivity to formula ingredients. Subject eligibility 
was assessed via questionnaire and physical measurements.  Refer to Appendix B for 
the eligibility screening questionnaire.  Fiber intake was screened using a fruit, 
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vegetable, and fiber frequency questionnaire (193).  Written informed consent was 
obtained from each subject and the study was approved by the University of 
Minnesota Institutional Review Board for Human Research Protection Program.  The 
informed consent form is listed in Appendix C.   
 
Subject protocol 
During the study, subjects consecutively consumed habitual diet for 14 days (run-in 
period), enteral diet 1 for 14 days, habitual diet for 28 days (washout phase), and 
enteral diet 2 for 14 days.  Enteral formula diets were randomly assigned and the two 
treatment sequences were given in equal numbers, stratified by gender.  See Appendix 
F for the randomization schedule.  Subjects exclusively consumed (orally) formula 
during the enteral periods except ad libitum consumption of water and coffee, tea and 
non-caloric/no-fiber containing beverages in similar amounts consumed during 
normal diet.  Subjects were provided with formula in excess of their total energy 
needs as calculated by the Harris-Benedict equation and adjusting with physical 
activity factors (194).  Subjects were allowed to consume formula ad libitum above 
their calculated needs, but were withdrawn from the study if their intake was below 
75% of the target volume for two consecutive days.  Formula was provided in 250 mL 
cans that were identically labeled with the exception of four different product codes 
(to ensure blinding). 
 
Subjects recorded diet records for 2 days during habitual diet and 14 days during the 
enteral formula periods.  Subjects anaerobically collected a fecal sample on the last 
day of each period as described in the in vitro section.  Samples were delivered to the 
laboratory within 1 h of defecation, and processed immediately.  Gas symptoms were 
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assessed via the gastrointestinal quality of life index questionnaire which was 
administered at the end of each period (132).  Refer to Appendix E for the complete 
GIQLI. 
 
Enteral formula and diet measurements 
Enteral formulas were nutritionally complete and identical in composition except for 
fiber content.  Base formula contained 6276 kJ/L, 67.6 g protein/L, 64.8 g fat/L, 168 g 
carbohydrate/L and fiber containing formula was base supplemented with 15 g/L of 
fiber blend.  The fiber blend was composed of a 50:50 insoluble: soluble mixture of 
FOS, pea hull fiber, gum acacia, and inulin.  Refer to Appendix D for the complete 
nutrition information and ingredient list for the formulas. 
 
Enteral formula energy and protein intake was calculated from 14-day diet records 
during the formula periods.  Enteral formula fiber intake was calculated from 14-day 
diet records during the fiber formula period.  Habitual diet reports were generated by 
entering the diet records into Nutrition Data System for Research (University of 
Minnesota, Version 2011).  Habitual diet energy, fiber, and protein intake values were 
averaged from the 2-day diet records recorded during the run-in and washout phases.   
 
Human subject fecal sample preparation 
Anaerobically packaged fecal samples were kneaded for 2 min to homogenize.  A 10 
g aliquot of fecal sample was diluted 1:10 (w/w) in phosphate buffered saline (PBS, 
0.1 M, pH 7.2).  The fecal: PBS mixture was homogenized in a stomacher for 2 min 
and the slurry was aliquoted for SCFA.  The remaining sample was used for pH 
measurement via calibrated pH probe. 
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In vitro and human subject short chain fatty acid measurement 
SCFA were completed in triplicate using a modified Schneider method (123).  In vitro 
fermentation liquid aliquots were thawed at 4 C.  To the fermentation liquid, 1.6 mL 
of distilled water and 0.4 mL 50% sulfuric acid was added and vortex mixed.  Two 
mL of diethyl ether and 2 µL 2-ethylbutyric acid (99%, internal standard) was added 
to each tube.  Tubes were sealed, vortex mixed and orbitally shaken at 300 rpm for 45 
minutes. Samples were centrifuged at 3000 rpm for 5 minutes and the supernatant was 
transferred to a test tube containing calcium chloride to remove residual water.  The 
final sample was filtered through a 0.2 µm nylon filter and placed into a 2 mL glass 
gas chromatography vial and sealed. 
 
For the human subjects samples, approximately 2 mL of PBS:stool slurry was 
centrifuged at 10,000 rpm for 10 min.  To 1 mL of fecal supernatant, 0.4 mL 50% 
sulfuric acid and 2 mL of ether containing 1 µL/mL 2-ethyl butyric acid (99%, 
internal standard) was added.  The sample was sealed, vortex mixed for 10 s and 
shaken at 300 rpm for 45 min.  The ether was retained, excess water removed with 
calcium chloride, and the final sample placed into a 2 mL glass gas chromatography 
vial and sealed. 
 
All SCFA samples were analyzed using a HP 5890 gas chromatograph (in split mode) 
equipped with a 30 m x 0.53 mm x 1µm film thickness Stabilwax-DA (Restek 
Corporation, Bellefonte PA) column.  The injection port was 220C, the detector 
240C, oven program 110C for 0.5 min followed by 10C/min to 180C and then 
50C/min to 240C, hold 3 min.  Acetate, propionate, and butyrate were quantified for 
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in vitro samples.  Acetate, propionate, isobutyrate, butyrate, isovalerate, and valerate 
were quantified for in vivo samples.  All quantification was performed using standard 
curves generated from known amounts of acids and internal standard.   
 
Statistical Analysis 
All data analysis was performed in SAS (Version 9.2).  In vitro longitudinal repeated 
measurements were compared between fibers using a mixed-effects linear model, 
with a random intercept to model within-fiber correlation.  Gas volume was log 
transformed before analysis.  To adjust for multiple comparisons, differences were 
considered significant at P < 0.005. 
 
Baseline characteristics of human subject data were compared using a t-test.  All other 
human subject data was compared using longitudinal regression models with random 
subject effect to model the within-subject correlation.  For each outcome, period, 
gender and unequal carryover effects were tested for.  Data collected during the initial 
habitual diet and washout periods were combined and adjusted for period effects.  
Differences were considered significant at P < 0.05.    
 
Results 
In vitro fermentation study 
Three volunteers (aged 24-32; one male, two female) provided fecal samples for the 
fermentation.  Samples were pooled and used in the fermentation.   
 
All fiber:fecal slurries produced more than 3 mL gas during the 24 h fermentation 
except the control and pea fiber (Figure 3-1).  At 4 h, gas production was the highest 
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for inulin followed by 10 times less gas for FOS and gum acacia and essentially no 
gas from the fiber blend.  By 8 h, inulin and FOS produced approximately 20 times 
more gas than the fiber blend.  At 12 h, inulin and FOS continued to have the highest 
gas production (and statistically similar) which was three times higher than the gum 
acacia and five times more than the fiber blend.  At the final 24 h timepoint, FOS and 
inulin produced the most (and statistically similar) amount of gas, followed by gum 
acacia (which was similar to FOS levels). The blend produced intermediate amounts 
at approximately a quarter of that produced by inulin and FOS.  Gas volume values 
for each fiber and statistical significance can be found in Table 3-1.   
 
 
Due to the fermentation media used, the initial pH of the system was approximately 9, 
and no statistical differences were found between any fibers at time 0 (Table 3-2).  At 
4 h, the FOS and inulin both had dropped approximately 3 pH units from baseline 
(time 0) and were significantly lower than all other fibers.  Statistically different, but 
somewhat higher than FOS and inulin was the fiber blend (pH 6.5), followed by 
approximately pH neutral values for the outer pea, gum acacia and control.  At 8 h, 
the inulin and FOS continued to have the lowest (and statistically similar) pH, 
followed by (in increasing pH) fiber blend and gum acacia.  Outer pea and control 
remained approximately pH neutral.  By 12 h, FOS and inulin had the lowest (and 
similar) pH at approximately 5.9 with increased and similar values for the fiber blend 
and gum acacia (~pH 6.5), followed by the pH neutral outer pea and control.  At the 
end of the 24 h fermentation, the control continued to remain approximately neutral 
followed by (highest to lowest) outer pea, fiber blend, inulin and gum acacia and 
FOS.   
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Total SCFA production (sum of acetate, propionate, and butyrate) from the in vitro 
fermentation is shown in Figure 3-2.  At baseline (time 0), all fiber samples had 
similar SCFA values except fiber blend which was 7-10 mmol/L lower than the rest.  
At 4 h, FOS and inulin had the highest (and similar) SCFA values.  Gum acacia and 
outer pea had intermediate concentrations of SCFA while the control and outer pea 
fiber had the lowest values.  By 8 h, inulin had the highest production which was 
statistically different from all other fibers.  FOS, fiber blend, gum acacia and outer 
pea had intermediate values with the control the lowest.  At 12 h inulin continued to 
have the highest SCFA followed by (in decreasing concentration) FOS, gum acacia, 
fiber blend, control and outer pea.  At the conclusion of the fermentation, inulin 
produced the highest SCFA which was statistically similar to FOS.  Gum acacia 
produced similar amounts of SCFA as FOS and these were not statistically 
distinguishable from fiber blend, pea fiber or control. Total SCFA values for each 
fiber and statistical significance can be found in Table 3-3. 
 
Enteral nutrition human feeding study 
Twenty-four subjects were enrolled, and twenty subjects (10 men, 10 women) 
completed the study.  The mean age and BMI of the women and men did not 
significantly differ. Overall mean subject age was 25.8 (+/- 9.9 SD) with a BMI of 
25.8 (+/- 2.5 SD).  Baseline characteristics of the two sequence groups were also 
compared, and no statistical differences were found.  Subject diet characteristics are 
listed in Table 3-4. 
 
pH and SCFA 
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Human samples were analyzed for both SCFA and branched chain fatty acids 
(BCFA).  Total SCFA refers to total amounts of acetate, propionate, and butyrate.  
Total BCFA refers to amounts of isobutyrate, isovalerate and valerate.  SCFA and 
BCFA are reported per mL of fecal water.   
 
Total SCFA were approximately 2 times higher during the habitual diet phase than 
during the formula phases (p<0.0001, Table 3-5).  Between the formula periods, 
SCFA on the fiber blend was 1.1% higher than the fiber free formula (p=0.029).  
Individual SCFA also differed; butyrate proportion was approximately 1.6 times 
higher in the habitual diet compared to both formulas (both p < 0.0001), and 1% 
higher in the fiber free formula compared to the fiber formula (p=0.041).  Propionate 
was in a lower proportion in habitual diet than both formula diets (both p <0.03), but 
did not differ between formulas.  Acetate was also in a lower proportion during 
habitual diet than both formulas (both p<0.0001) and did not differ between formulas.  
Total BCFA were 1% higher in habitual diet compared to the fiber blend formula 
(p=0.046), but fiber free did not statistically differ from habitual diet or fiber blend 
formula.  Formula diet pH did not differ, and both were a pH unit higher than habitual 
diet (both p<0.001). 
 
The incidence of gas and bloating symptoms was monitored during each diet.  
Symptom scores were as follows (higher scores indicate more favorable outcomes); 
habitual 17.3 (+/- 0.4 SE), fiber free formula 17.3 (+/- 0.4 SE), and fiber blend 
formula 18.0 (+/- 0.4 SE).  Incidence of gas and bloating symptoms were not different 
between formulas or between either formula and habitual diet.   
 
  85 
Discussion 
Fiber source and structure, as well as the bacterial populations present, affect fiber 
fermentation patterns in both in vitro and in vivo models (10, 56).  Fermentation leads 
to the production of acids, which are considered to be a beneficial product of 
fermentation, but also gas which can lead to reduced tolerance of fiber in vivo. Greater 
gas volume is perceived more in the proximal bowel compared to the distal colon, so 
rapidly fermented fibers would be expected to cause more gastrointestinal intolerance 
than those that are more slowly fermented (205).  Human studies have found that 
dietary supplementation with short chain fibers such as FOS and inulin lead to 
increased side effects (170, 171, 211).  In contrast, complex molecules, such as gum 
acacia are tolerated at doses up to 40 g/day, and a 1:1 combination of gum acacia and 
FOS fed to humans led to reduced gastrointestinal side effects than FOS alone (178, 
189).  Others have reported use of blends with fibers of varying chain length to 
attenuate gas production in vitro (128, 206).   
 
Our results demonstrate similar trends in gas production.  Fermentation of soluble 
shorter chain, single fibers (FOS and inulin) typically led to higher gas production at 
earlier time points (4 and 8 hours).  In contrast, gas production was almost 
undetectable at these time points for the larger and more complex soluble gum acacia, 
insoluble pea fiber and fiber blend.  Pea fiber has been shown to be poorly fermented 
and would be expected to contribute minimally to gas production (179).   While the 
fiber blend contains inulin, FOS, and gum acacia which are known to be fermentable, 
it also contains pea fiber which changed the fermentation pattern as a whole and 
resulted in delayed gas production until 12 and 24 hours.  The slower fermentation 
could lead to improved tolerance in vivo, as gas is perceived more in the proximal 
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bowel (205).  The results of the human feeding study were parallel to the in vitro gas 
production from the fiber blend.  No differences in gas and bloating were detected 
between any diet suggesting that the fiber blend did not induce symptoms beyond 
subject’s normal levels and was well tolerated at the dose delivered.   
 
In general, in vitro pH changes were consistent with changes in gas production.  pH 
values were lower at earlier time points for substrates comprised entirely of rapidly 
fermented, short chain fructans (FOS, inulin).  Hernot et al found the greatest decrease 
in pH for FOS and inulin after 8 hours fermentation, which is consistent with our 
results (206).  Addition of higher molecular weight molecules resulted in a delayed 
decrease in pH consistent with more gradual fermentation. Gum acacia maintained a 
relatively high pH until 24 hours, where it decreased to values lower than the single 
fiber treatments.  Similarly, the blend had a significantly lower pH than the control 
and pea fiber which can be attributed to delayed fermentation of the gum acacia 
fraction of the blend.   
 
Fecal pH of the human samples, however, was not as definitive.  Fecal pH during the 
fiber formula and the fiber free formula was the same despite an average fiber dose of 
19 g on the fiber formula.  Although a significant portion is the minimally 
fermentable pea fiber, it is not clear why the fecal pH was not decreased.  A possible 
explanation is an increase in bicarbonate from the proposed SCFA-bicarbonate 
absorption mechanism (45).  Furthermore, pH was lower during the habitual diet than 
during the formula diets despite receiving an average of 3 g less fiber per day.  This 
may be explained by the shorter transit times during the habitual diet (data not 
presented) which would allow for less time for SCFA absorption to occur.   
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In vitro total SCFA production followed a similar pattern as gas and pH, although 
significant differences between treatments were more difficult to detect due to high 
standard errors.  Among the single fiber treatments, total SCFA levels were higher at 
early time points for inulin and FOS compared to gum acacia and pea fiber.  Later in 
the fermentation, total levels were difficult to statistically distinguish, but inulin 
produced the greatest SCFA levels overall.  Since SCFAs are a product of 
fermentation, these results are consistent with rapid fermentation of short chain 
molecules, and delayed fermentation of fibers with higher molecule weight.  More 
gradual fermentation may translate into increased SCFA production throughout the 
entire colon, which may have additional health benefits (166).  
 
In vivo SCFA are more complex. In mixed diets, bacteria ferment carbohydrates to 
primarily produce linear SCFA while protein fermentation leads to the production of 
BCFA and less desirable metabolites such as ammonia, phenol, and indole (56). 
Absorption of SCFA is thought to occur via ionic exchange and nonionic diffusion 
and in human rectal studies, absorption rates can be manipulated by changing 
electrolyte composition (212).  Furthermore, in an animal model, acetate absorption 
rates increased with increasing concentration (124).  Fecal SCFA, then, reflect 
residual SCFA after both production and absorption.  Fecal SCFA of the subjects on 
habitual diet was approximately 2 times higher than both of the formulas, although it 
should be noted that the whole gut transit times were approximately 1.5 times longer 
on the formula diet versus the habitual diet.  Longer transit times may influence 
SCFA and water absorption (213).  Between formulas, the fiber blend formula had 
increased SCFA concentration compared to the fiber free formula and transit time was 
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not different.  This may be due to more substrate present for bacteria to ferment, 
although because concentration may influence absorption, it is difficult to make a 
conclusion.  Similarly, it is difficult to draw conclusions regarding the proportions of 
SCFA measured in the fecal samples since differences may be due to production or 
absorption. BCFA are produced during protein fermentation, and although they are 
not detrimental, reflect a process that also produces phenols, indoles, etc. which are 
undesirable.  Little has been published on BCFA in human samples. Measured levels 
were the highest on habitual diet despite similar protein intakes between the habitual 
and formula diets.  Again, transit time may have contributed to differences.  Between 
the two formulas, it was surprising that the fiber free samples did not have higher 
BCFA since the diet was devoid of fiber and the substrates reaching the colon would 
be undigested formula, and endogenous mucus, sloughed off cells, and digestive 
secretions (56).  Although these substances would also be present during the fiber 
containing formula, carbohydrate fermentation is preferred over protein metabolism 
and it was hypothesized that BCFA would be found in lower amounts (119). 
 
Conclusions 
Overall, the fermentation of fibers with a range of physicochemical properties yielded 
differing profiles of pH, gas and SCFA.  By blending insoluble and soluble fibers, an 
intermediate fermentation profile was observed and this blend was well tolerated 
when fed to healthy human subjects.  During the human intervention study, fecal 
SCFA was increased on the fiber containing formula compared to the fiber free which 
may have indicated increased fermentation in the gut.   
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Figure 3-1. Gas volume produced during 24 h batch in vitro fermentation of fibers
1,2
 
 
1
Values are geometric means. 
2
FOS: Fructo-oligosaccharides 
 
 
 
 
 
 
 
 
 
 
 
 
 
  91 
Figure 3-2. Total short chain fatty acids produced during 24 h batch in vitro 
fermentation of fibers
1,2
 
 
1
Values are means.  Total short chain fatty acids refers to the sum of acetate, 
propionate, and butyrate. 
2
FOS: fructo-oligosaccharides 
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Table 3-1. Gas volume produced during 24 h in vitro fermentation of fibers
1
 
 Gas volume 
(mL) 
   
Fiber 4 h 8 h 12 h 24 h 
Inulin 
 
22.6 (6.5, 
78.4)
bc
 
62.2 (40.1, 
96.6)
c
 
76.3 (66.8, 
87.2)
d
 
100.3 (90.0, 
111.8)
d
 
FOS 
 
1.8 (0.5, 6.1)
ac
 55.2 (35.6, 
85.7)
c
 
68.7 (60.1, 
78.4)
d
 
83.7 (75.1, 
93.2)
ad
 
Gum acacia 
 
1.6 (0.5, 
5.6)
ab
 
0.5 (0.3, 0.8)
a
 26.9 (23.5, 
30.7)
a
 
73.5 (66.0, 
81.9)
a
 
Fiber blend 
 
0.5 (0.1, 1.7)
a
 2.5 (1.6, 3.9)
b
 12.6 (11.0, 
14.4)
b
 
24.6 (22.1, 
27.4)
b
 
Outer Pea 
 
0.5 (0.1, 1.7)
a
 0.5 (0.3, 0.8)
a
 0.5 (0.5, 0.5)
c
 2.3 (2.1, 2.6)
e
 
Control 
 
0.9 (0.4, 2.2)
a
 0.5 (0.4, 0.7)
a
 0.5 (0.5, 0.6)
c
 0.5 (0.5, 0.5)
c
 
1
Geometric mean (95% CI).  Different letters indicate significantly different values (p 
< 0.005) within each time point (column). 
 
 
 
 
 
 
 
  93 
Table 3-2. pH during 24 h batch in vitro fermentation of fibers
1 
 pH     
Fiber 0 h 4 h 8 h 12 h 24 h 
FOS 
 
9.09 
(0.26)
a
 
5.82 
(0.10)
c
 
5.62 
(0.09)
d
 
5.86 
(0.08)
c
 
6.04 
(0.08)
d
 
Inulin 
 
9.01 
(0.26)
a
 
5.81 
(0.10)
c
 
5.81 
(0.09)
d
 
5.93 
(0.08)
c
 
5.88 
(0.08)
a
 
Gum 
acacia 
 
9.02 
(0.26)
a
 
7.12 
(0.10)
a
 
6.79 
(0.09)
a
 
6.54 
(0.08)
a
 
5.87 
(0.08)
a
 
Outer pea 
 
9.13 
(0.26)
a
 
6.98 
(0.10)
a
 
6.99 
(0.09)
c
 
6.85 
(0.08)
b
 
6.76 
(0.08)
e
 
Fiber 
blend 
 
8.98 
(0.26)
a
 
6.5 (0.10)
b
 6.48 
(0.09)
b
 
6.43 
(0.08)
a
 
6.37 
(0.08)
b
 
Control 
 
9.05 
(0.26)
a
 
7.07 
(0.09)
a
 
6.99 
(0.08)
c
 
6.91 
(0.08)
b
 
6.86 
(0.07)
c
 
1
Mean (SEM).  Different letters indicate statistically different values within 
timepoints (column) at p<0.005. 
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Table 3-3. Total short chain fatty acids produced during 24 h in vitro fermentation of 
fibers
1 
 
 Total  
SCFA 
(mmol/L) 
    
Fiber 0 h 4 h 8 h 12 h 24 h 
FOS 
 
115 (4)
a
 238 (28)
a
 322 (23)
a
 487 (34)
ac
 531 (59)
acd
 
Inulin 
 
115 (4)
a
 244 (28)
a
 431 (23)
c
 598 (59)
c
 643 (59)
c
 
Gum 
acacia 
116 (4)
a
 214 (29)
ac
 255 (23)
ab
 356 (34)
abd
 513 (59)
ad
 
Outer pea 
 
112 (4)
ab
 189 (29)
cd
 256 (23)
a
 215 (34)
d
 316 (70)
d
 
Fiber 
blend 
105 (4)
b
 131 (28)
b
 267 (23)
ab
 309 (34)
bd
 214 (59)
bd
 
Control 
 
112 (3)
a
 154 (27)
bd
 215 (18)
b
 220 (24)
bd
 230 (54)
bd
 
1
Mean (SEM).  Total short chain fatty acids refers to the sum of acetate, propionate 
and butyrate. Different letters are significantly different (p < 0.005) within time points 
(column). 
 
 
 
 
  95 
Table 3-4. Energy, fiber and protein intake of 20 human subjects consuming enteral 
formula and habitual diet
1
 
 Habitual    Formula    
  Energy
2
 
(kJ/d) 
Fiber
2
 
(g/d) 
Protein
2
  
(g/d) 
Energy
3
  
(kJ/d) 
Fiber
4
 
(g/d) 
Protein
3
 
(g/d) 
Women  
(n=10) 
8008 
(2426) 
16.8 
(4.2) 
71.5 
(21.4) 
6757 
(853) 
16.2 
(1.9) 
72.8 
(9.2) 
Men 
(n=10) 
9301 
(2506) 
15.1 
(6.5) 
102.4 
(27.9) 
9309 
(1451) 
21.6 
(3.8) 
100.3 
(15.6) 
Total 
(n=20) 
8656 
(2485) 
16.0 
(5.3) 
89.6 
(29.2) 
8067 
(1745) 
18.9 
(4.0) 
86.5 
(18.8) 
1
Mean (SD).  
2
Habitual diet energy, fiber and protein intake was calculated by combining 2-day diet 
records from the run-in and washout periods.  Values were generated by entering the 
diet records into Nutrition Data System for Research (University of Minnesota, 
Version 2011) 
3
Enteral formula energy and protein intake was calculated from 14-day diet records 
during the formula periods. 
4
Enteral formula fiber intake was calculated from 14 day diet records during the fiber 
formula period. 
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Table 3-5. Fecal short chain fatty acids and pH of human subjects consuming fiber 
free formula, fiber blend formula and habitual diet
1
 
 Habitual diet Fiber free 
formula 
Fiber blend 
formula 
Total SCFA
2
 
(mmol/L) 
80.9 (2.7)
a
 39.7 (2.3)
b
 43.5 (2.3)
c
 
Acetate % 39.5 (0.6)
a
 49.2 (1.0)
b
 50.2 (0.9)
b
 
Propionate % 29.7 (1.1)
a
 31.6 (1.3)
b
 31.5 (1.3)
b
 
Butyrate % 30.7 (1.1)
a
 19.2 (0.8)
b
 18.3 (0.8)
c
 
Total BCFA
3
 
(mmol/L) 
11.5 (1.2)
a
 10.5 (1.1)
ab
 10.1 (1.1)
b
 
pH 6.52(0.07)
a
 7.50(0.09)
b
 7.54 (0.09)
b
 
1
Mean (SEM).  Different letters indicate statistically different values between diets 
(within row comparisons) at p<0.05. 
2
Total SCFA refers to the sum of acetate, propionate and butyrate. 
3
Total BCFA refers to the sum of isobutyrate, isovalerate, and valerate. 
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Appendix A: Sample Size Calculation   
The sample size of the human study was powered to detect differences in stool 
weight.  The power/sample size calculation was based on the stool weight data 
reported in Table 4 of the Whelan et al paper (48) who compared enteral formula 
containing FOS and pea fiber with standard fiber-free formula.    Whelan reported 
mean stool weight +/- standard deviations of: 
 
Habitual diet     132.4 + 68.5 g/day 
 Fiber-free enteral formula  48.3 + 30.1 g/day 
 Fiber-containing enteral formula 73.2 + 37.5 g/day 
  
Assuming standard deviations of 30 and 38 for the two treatments, and a within-
subject correlation of 0.6, a sample of 20 subjects is required for this crossover to 
have at least 80% power to detect a difference of 21g/day at the 0.05 level between 
the two study treatments.  This minimum detectable difference is smaller than the 
difference of 25 g/day found by (48). 
 
The POWER Procedure 
 
Paired t Test for Mean Difference 
 
Fixed Scenario Elements 
Distribution Normal 
Method Exact 
Mean Difference 21 
Standard Deviation 1 30 
Standard Deviation 2 38 
Correlation 0.6 
Number of Pairs 20 
Number of Sides 2 
Null Difference 0 
Alpha 0.05 
 
Computed Power 
Power 
0.814 
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Appendix B:  Subject Eligibility Screening Questionnaire 
Thank you for your interest in participating in our study. Before I can determine if 
you meet the criteria to participate in the study, I need your responses to the following 
questions.  After receiving your responses, I will inform you whether or not you meet 
the criteria for the study.  If you do not meet the criteria for the study, I will destroy 
the information collected.  
NAME                                                                DATE ____________________ 
DATE OF BIRTH : _____________________AGE______________________ 
HT_______  WT___________              (office use : BMI ____ ) 
1.  Do you smoke or chew tobacco now?   
2.  For women, are you currently pregnant or lactating?  
3.  Have you taken antibiotics within the last 6 months?     
4.  Do you currently take laxatives?       
5.  Are you currently taking any prescription medications other than oral 
contraceptives? 
6.  Do you take any over the counter medications such as aspirin, ibuprofen, etc.?  
If yes, list;  
7.  Have you ever been diagnosed with the following diseases or conditions?        
Diabetes (type I or type II), Cancer (any type), Kidney disease,  Liver disease, Binge 
eating disorder , Ulcerative Colitis, Crohns Disease, Any other gastrointestinal 
conditions 
8.  Have you consumed probiotic foods, such as yogurt, kefir, kimchi, etc. in the last 
month?  
If yes, how much and how frequently? 
9. Think about your eating habits over the past year or so. About how often do you eat 
each of the following foods? Remember breakfast, lunch, dinner, snacks and eating 
out. Check one radio button for each food.  Enter answers at: 
http://www.nutritionquest.com/wellness/free-assessment-tools-for-individuals/fruit-
vegetable-fiber-screener/ 
 
 
  115 
Fruits, Vegetables, and 
Grains 
Less than 
1/WEEK 
Once a 
WEEK 
2-3 times 
a WEEK 
4-6 times 
a WEEK 
Once 
a 
DAY 
2+ a 
DAY 
Fruit juice, like orange, 
apple, grape, fresh, frozen 
or canned. (Not sodas or 
other drinks) 
      
How often do you eat any 
fruit, fresh or canned (not 
counting juice?) 
      
Vegetable juice, like 
tomato juice, V-8, carrot       
Green salad       
Potatoes, any kind, 
including baked, mashed 
or french fried 
      
Vegetable soup, or stew 
with vegetables       
Any other vegetables, 
including string beans, 
peas, corn, broccoli or any 
other kind 
      
Fiber cereals like Raisin 
Bran, Shredded Wheat or 
Fruit-n-Fiber 
      
Beans such as baked 
beans, pinto, kidney, or 
lentils (not green beans) 
      
Dark bread such as whole 
wheat or rye       
   
 
10.  Do you currently exercise more than 2 hr./week?   
 
Please describe your exercise routine.  If you do not have an exercise routine, please 
describe your activity. 
 
11.  Are you a vegetarian?  
12.  Do you have any food or other allergies? 
If YES, what are they? 
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13.  Do you take ANY supplements? This includes vitamin/mineral supplements, 
fiber supplements like Metamucil or Citrucel, pre or probiotic supplements,  herbal 
supplements, etc.    
 
If yes, please list the supplements and the dose/frequency: 
14.  Have you participated or are currently participating in a research study?  
If yes, when?  
15.  Have you lost or gained weight in the past 3 months or are trying to gain or lose 
weight currently?  
If yes, how much?  
16.  For women, have you gone through menopause?  
17.  This study requires you to consume a liquid nutrition product (similar to Ensure) 
for two 14 day periods exclusively (with the exception of non-caloric beverages such 
as coffee, tea, and water).   Are you willing and able to do this?  
18.  This study will require you to collect fecal samples for the last five days of each 
study treatment (4 treatment periods).  Are you willing and able to do this?  
 
19.  The fecal collection on the last day of each treatment period needs to be delivered 
to the study coordinator within 1 hr. of defecation.  This means, during the entire 
study, four samples will need to be delivered within 1 hr.  Are you willing and able to 
do this? 
 
20.  This study will require you to record diet records, consume a capsule of plastic 
pellets for a measurement, and fill out a 36 question questionnaire 4 different times.  
Are you willing and able to do this?   
 
21.  This study will include 6 visits to McNeal Hall on the St. Paul Campus of the 
University of Minnesota.  Each visit will last approximately 30 min.  Are you willing 
to do this? (We cover parking expenses)  
 
22.  Do you have reliable transportation?  
23.  Do you travel out of the Twin Cities area frequently?    
24.  Are there specific dates you will not be available (holidays, etc)?   
25.  After hearing about the study, how do you feel about the time commitment and 
effort involved to complete the study?  
ADDRESS_______________________________________________________ 
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CITY____________________ STATE________ ZIP___________ 
TELEPHONE NUMBERS:  work (daytime):_____________________ 
Home (evening):_______________________________________ 
Email: ________________________ 
Best time of day to be reached ______________________ 
Comments: 
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Appendix C: Approved Subject Consent Form 
 
GUT HEALTH RESPONSE TO A NEW FIBER BLEND STUDY CONSENT 
FORM 
 
 
You are invited to participate in a research study of dietary fibers and their effects on 
gut health. You were selected as a possible participant because you are a healthy 
individual that meets the study population criteria. We ask that you read this form and 
ask any questions you may have before agreeing to be in the study. 
 
This study is being conducted by Joanne Slavin, Ph.D., RD and Katie Koecher, B.S. 
in the Department of Food Science and Nutrition. The Department of Food Science 
and Nutrition at the University of Minnesota is in the College of Food, Agricultural 
and Natural Resource Sciences.  The study is funded by Nestle Research Center. 
 
Part 1.  Study Purpose   
 
The purpose of the study is to examine the effects of dietary fiber on gut health.   The 
results of the study will be used to assess the gut health benefits of adding fibers to a 
liquid food product.  The fibers included in this study will be added to the liquid 
nutrition drink (complete nutrition source) and both the fibers and drink are food 
products currently on the market and are safe to consume.  Fiber levels in the liquid 
nutrition drink, as part of a complete nutrition source, are in similar amounts to the 
recommended dietary guidelines.   
 
Part 2. Study Procedures 
 
In total, approximately 20 subjects will participate in this study.  If you agree to 
participate, we would ask you to do as follows. 
 
The study consists of six visits to the Food Science and Nutrition Department at the 
University of Minnesota while completing four pre-planned study phases in the 
subject’s home (or site of choice).  At each visit, subjects will receive information and 
materials for completing the corresponding phase of the study.  The study is organized 
into four phases; regular diet (initial) for 14 days, liquid diet 1 (14 days), regular diet 
(washout-28 days), and liquid diet 2 (14 days).  During each phase subjects will 
complete food intake records, consume a gelatin capsule of pellets for measurement 
of gastrointestinal transit time, fill out a gastrointestinal health survey (36 questions) 
and collect fecal samples during the last five days of each phase.  At certain visits, 
subjects will deliver their completed records and fecal samples from the previous 
study phase.  A schedule of the visits and corresponding events will be given to you in 
addition to thoroughly discussed.   
 
Description of specific visit information: 
 
The initial visit will include height and weight measurements.  At the first visit, the 
stool sample collection kits, diet records, gastrointestinal survey, and the capsule of 
the pellets will be provided along with a schedule of events to assist you during the 
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regular diet (initial) phase.  Diet records will be filled out during days 1-14, transit 
time pellet capsule will be consumed on day 8, the gastrointestinal (GI) survey will be 
filled out on day 14, and total fecal samples will be collected day 9-13.  The fecal 
collection on day 13 will require a special collection procedure and will need to be 
delivered to the study coordinator within an hour of defecation.  At the conclusion of 
the initial diet, subjects will have visit 2.   
 
During visit 2, fecal samples, the GI survey and diet records will be delivered to the 
laboratory.  In addition, during visit 2 the stool sample collection kits, diet records, 
gastrointestinal survey, transit time capsule, and liquid diet 1 will be provided for the 
next study phase (liquid diet 1).  You will be given information on how much liquid 
diet to consume based on your height, weight and activity level such that you 
maintain body weight.  The liquid diet is to be consumed exclusively except for non-
caloric, non fiber containing, liquids such as sugar free flavoring, coffee, tea, and 
water.  Again, the liquid diet is a complete nutrition source.  During liquid diet 1 
phase, diet records will be filled out for days 14-28, transit time capsule will be 
consumed on day 22, the GI survey will be filled out on day 28, and total fecal 
samples will be collected days 23-27.  The fecal collection on day 27 will require a 
special collection procedure and will need to be delivered to the study coordinator 
within an hour of defecation.  At the conclusion of the liquid diet 1 phase, subjects 
will have visit 3.   
 
During visit 3, fecal samples and the survey and diet records will be delivered to the 
laboratory.  In addition, during visit 3, the stool sample collection kits, diet records, 
gastrointestinal survey, and transit time capsule will be provided along with a 
schedule of events to assist you during the regular diet (washout phase).  The washout 
phase will last 28 days, and diet records will be filled out during days 42-56, transit 
time capsule will be consumed on day 50, the gastrointestinal survey will be filled out 
on day 56 and total fecal samples will be collected days 51-55.  The fecal collection 
on day 55 will require a special collection procedure and will need to be delivered to 
the study coordinator within an hour of defecation.   At the conclusion of the washout 
phase, subjects will have visit 4. 
 
During visit 4, fecal samples and the survey and diet records will be delivered to the 
laboratory.  In addition, during visit 4 the stool sample collection kits, diet records, 
gastrointestinal survey, transit time capsule, and liquid diet 2 will be provided for the 
next study phase (liquid diet 2).  You will be given information on how much liquid 
diet to consume based on your height, weight and activity level such that you 
maintain body weight.  The liquid diet is to be consumed exclusively except for non-
caloric, non fiber containing, liquids such as sugar free flavoring, coffee, tea, and 
water.  Again, the liquid diet is a complete nutrition source.  During liquid diet 2 
phase, diet records will be filled out for days 56-70 transit time capsule will be 
consumed on day 64, the gastrointestinal survey will be filled out on day 70, and total 
fecal samples will be collected days 65-69.  The fecal collection on day 69 will 
require a special collection procedure and will need to be delivered to the study 
coordinator within an hour of defecation.  At the conclusion of the liquid diet 2 phase, 
subjects will have visit 5.   
 
During visit 5, fecal samples and the survey and diet records will be delivered to the 
laboratory.   
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It will take approximately three months to complete the entire study.  All procedures 
in this study have been completed by subjects before (none are experimental).  
 
Part 3. Risks of Study Participation 
 
The fibers used in this study are provided in amounts commonly taken in foods and 
are already used in commercial foods available in the United States.  Addition of fiber 
to liquid nutrition products has no known risks, although some fibers may cause 
intestinal gas and loose stools in some individuals. 
 
Part 4.  Benefits of Study Participation 
 
There is no direct benefit by participating in this study. 
 
Part 5.  Alternatives to Study Participation 
  
The alternative is to not participate in this study.  You may consume fiber without 
participating in this study. 
 
Part 6.  Study Costs/Compensation 
 
Study related visits, procedures, and supplies (including the liquid nutrition drink) 
will be provided at no cost to you.  Subjects will receive $200 upon completion of 
first liquid diet phase.  An additional $800 payment will be disbursed to the subject 
upon completing the second liquid diet phase (completion of the entire study).  Please 
note, if you withdraw from the study, you are required to return any remaining study 
product to the researchers.  
 
Part 7.  Research Related Injury 
 
In the event that this research activity results in an injury, treatment will be available, 
including first aid, emergency treatment and follow-up care as needed. Care for such 
injuries will be billed in the ordinary manner to you or your insurance company. If 
you think that you have suffered a research related injury, seek immediate medical 
care and inform the study investigator/staff as soon as possible. 
 
Part 8.  Confidentiality 
 
The records of this study will be kept private. In any publications or presentations, we 
will not include any information that will make it possible to identify you as a subject. 
Your record for the study may, however, be reviewed by Nestle Research Center and 
by departments at the University with appropriate regulatory oversight.  To these 
extents, confidentiality is not absolute.  
 
Part 9.  Protected Healthy Information 
 
Your PHI created or received for the purposes of this study is protected under the 
federal regulation known as HIPAA.  Refer to the attached HIPAA authorization for 
details concerning the use of this information.  
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Part 10.  Voluntary Nature of the Study 
 
Participation in this study is voluntary. Your decision whether or not to participate in 
this study will not affect your current or future relations with the University of 
Minnesota. If you decide to participate, you are free to withdraw at any time without 
affecting those relationships.   
 
Part 11.  Contacts and Questions 
 
The researchers conducting this study are Joanne Slavin and Katie Koecher.  You may 
ask any questions you have now, or if you have questions later, you are encouraged 
to contact them at 612-624-7234 or 612-624-4793.  
 
If you have any questions or concerns regarding the study and would like to talk to 
someone other than the researcher(s), you are encouraged to contact the Fairview 
Research Helpline at telephone number 612-672-7692 or toll free at 866-508-6961.  
You may also contact this office in writing or in person at University of Minnesota 
Medical Center, Fairview-Riverside Campus, 2200 Riverside Avenue, Minneapolis, 
MN 55454. 
 
You will be given a copy of this form to keep for your records. 
 
 
Statement of Consent 
 
I have read the above information.  I have asked questions and have received answers.  
I consent to participate in the study. 
 
Signature of Subject_______________________________________________  
 
Date_________________ 
 
Signature of Investigator___________________________________________  
 
Date_________________ 
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Appendix D - Enteral Product Nutrition Information and Ingredient List 
Control (fiber free) formula 
Nutrition 1 x 8.45 fl oz can 
Information     
  Contents Units 
Serving Size 250 ml 
Calories 375   
Protein 16.9 G 
Carbohydrate 42.0 G 
Fat 16.2 G 
Sodium 322 MG 
Potassium 536 MG 
Vitamin A
1
 2680 IU 
Vitamin C 80.4 MG 
Thiamin 0.8 MG 
Riboflavin 0.91 MG 
Niacin 10.7 MG 
Calcium 268 MG 
Iron 4.82 MG 
Vitamin D 107 IU 
Vitamin E 16.1 IU 
Vitamin B6 1.07 MG 
Folic Acid 161 MCG 
Vitamin B12 3.22 MCG 
Phosphorus 268 MG 
Iodine 40.2 MCG 
Magnesium 107 MG 
Zinc 8.04 MG 
Copper 0.54 MG 
Biotin 121 MCG 
Pantothenic Acid 5.36 MG 
Vitamin K 21.4 MCG 
Choline 134 MG 
Chloride 402 MG 
Manganese 0.54 MG 
Selenium 18.8 MCG 
Chromium 32.2 MCG 
Molybdenum 20.1 MCG 
L-Carnitine 26.8 MG 
Taurine 26.8 MG 
Ingredients:  Water, maltodextrin, sucrose, sodium caseinate (milk), canola oil, 
medium chain triglycerides, calcium caseinate, soybean oil, potassium citrate, calcium 
phosphate tribasic, magnesium chloride, sodium citrate, artificial flavor, soy lecithin, 
sodium ascorbate, choline chloride, taurine, l-carnitine, zinc sulfate, alpha tocopheryl 
acetate, niacinabmide, ferrous sulfate, calcium pantothenate, copper gluconate, 
BHA/BHT (to preserve freshness), pyridoxine hydrochloride, thiamine hydrochloride, 
manganese sulfate, beta carotene, riboflavin, vitamin A palmitate, folic acid, biotin, 
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chromimum chloride, potassium iodide, sodium molybdate, sodium selenite, 
phytonadione, cyanocobalamin, cholecalciferol 
 
Fiber blend formula 
Nutrition 1 x 8.45 fl oz can   
Information     
  Contents  Units 
Serving Size 250 ml 
Calories 375   
Protein 16.9 G 
Carbohydrate
1
 42.0 G 
Fat 16.2 G 
Sodium 322 MG 
Potassium 536 MG 
Vitamin A
2
 2680 IU 
Vitamin C 80.4 MG 
Thiamin 0.8 MG 
Riboflavin 0.91 MG 
Niacin 10.7 MG 
Calcium 268 MG 
Iron 4.82 MG 
Vitamin D 107 IU 
Vitamin E 16.1 IU 
Vitamin B6 1.07 MG 
Folic Acid 161 MCG 
Vitamin B12 3.22 MCG 
Phosphorus 268 MG 
Iodine 40.2 MCG 
Magnesium 107 MG 
Zinc 8.04 MG 
Copper 0.54 MG 
Biotin 121 MCG 
Pantothenic Acid 5.36 MG 
Vitamin K 21.4 MCG 
Choline 134 MG 
Chloride 402 MG 
Manganese 0.54 MG 
Selenium 18.8 MCG 
Chromium 32.2 MCG 
Molybdenum 20.1 MCG 
L-Carnitine 26.8 MG 
Taurine 26.8 MG 
 
Ingredients:  Water, maltodextrin, sucrose, sodium caseinate (milk), canola oil, 
medium chain triglycerides, calcium caseinate, soybean oil, pea fiber, potassium 
citrate, calcium phosphate tribasic, magnesium chloride, gum acacia, oligofructose, 
sodium citrate, inulin, artificial flavor, soy lecithin, sodium ascorbate, choline 
chloride, taurine, l-carnitine, zinc sulfate, alpha tocopheryl acetate, niacinamide, 
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ferrous sulfate, calcium pantothenate, copper gluconate, BHA/BHT (to preserve 
freshness), pyridoxine hydrochloride, thiamine hydrochloride, manganese sulfate, 
beta carotene, riboflavin, vitamin A palmitate, folic acid, biotin, chromium chloride, 
potassium iodide, sodium molybdate, sodium selenite, phytonadione, 
cyanocobalamin, cholecalciferol 
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Appendix E - Gastrointestinal Quality of Life Index 
The below gastrointestinal quality of life index is modified for “healthy subjects” as 
defined by (132).  Scoring is listed below; subjects were given a version with no 
numerical values associated with the answers. 
 
1.  How often during the past 2 weeks have you had pain in the abdomen? 
 
All of the time 0 most of the time 1 some of the time 2 a little of the time 
3 never 4 
 
 
2.  How often during the past 2 weeks have you had a feeling of fullness in the 
upper abdomen? 
 
All of the time 0 most of the time 1 some of the time 2 a little of the time 
3 never 4 
 
 
3.  How often during the past 2 weeks have you had bloating (sensation of too 
much gas in the abdomen)? 
 
All of the time 0 most of the time 1 some of the time 2 a little of the time 
3 never 4 
 
 
4.  How often during the past 2 weeks have you been troubled by the excessive 
passage of gas through the anus? 
 
All of the time 0 most of the time 1 some of the time 2 a little of the time 
3 never 4 
 
 
5.  How often during the past 2 weeks have you been troubled by strong burping 
or belching? 
 
All of the time 0 most of the time 1 some of the time 2 a little of the time 
3 never 4 
 
 
6.  How often during the past 2 weeks have you been troubled by gurgling noises 
from the abdomen? 
 
All of the time 0 most of the time 1 some of the time 2 a little of the time 
3 never 4 
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7.  How often during the past 2 weeks have you been troubled by frequent bowel 
movements? 
 
All of the time 0 most of the time 1 some of the time 2 a little of the time 
3 never 4 
 
 
8.  How often during the past 2 weeks have you found eating to be a pleasure? 
 
All of the time 4 most of the time 3 some of the time 2 a little of the time 
1 never 0 
 
 
9.  Because of your health, to what extent have you restricted the kinds of food 
you eat? 
 
Very much 0  much 1 somewhat 2  a little 3 not at all 4 
 
 
10.  During the past 2 weeks, how well have you been able to cope with everyday 
stresses? 
 
Extremely poorly 0 poorly 1 moderately 2  well 3  extremely 
well 4 
 
 
11. How often during the past 2 weeks have you been sad about your health? 
 
All of the time 0 most of the time 1 some of the time 2 a little of the time 
3 never 4 
 
 
12.  How often during the past 2 weeks have you been nervous or anxious about 
your health? 
 
All of the time 0 most of the time 1 some of the time 2 a little of the time 
3 never 4 
 
 
13.  How often during the past 2 weeks have you been happy with life in general? 
 
Never 0 a little of the time 1 some of the time 2 most of the time 3    all of 
the time 4 
 
 
14.  How often during the past 2 weeks have you been frustrated about your 
health? 
 
All of the time 0 most of the time 1 some of the time 2 a little of the time 
3 never 4 
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15.  How often during the past 2 weeks have you been tired or fatigued? 
 
All of the time 0 most of the time 1 some of the time 2 a little of the time 
3 never 4 
 
16.  How often during the past 2 weeks have you felt unwell? 
 
All of the time 0 most of the time 1 some of the time 2 a little of the time 
3 never 4 
 
 
17.  Over the past week, have you woken up in the night? 
 
Every night 0 5-6 nights 1 3-4 nights 2 1-2 nights 3 never 4 
 
 
18.  Due to your health, have you been troubled by changes in your appearance? 
 
A great deal 0     a moderate amount 1        somewhat 2 a little bit 3    not at all 
4 
 
 
19.  Due to your health, how much physical strength have you lost? 
 
A great deal 0     a moderate amount 1         somewhat 2 a little bit 3    
not at all 4 
 
 
20.  Due to your health, to what extent have you lost your endurance? 
 
A great deal 0     a moderate amount 1         somewhat 2 a little bit 3    
not at all 4 
 
 
21.  Due to your health, to what extent do you feel unfit? 
 
Extremely unfit 0 moderately unfit 1 somewhat unfit 2 a little unfit 3 
 fit 4 
 
 
22.  During the past 2 weeks, how often have you been able to complete your 
normal daily activities (school, work, household)? 
 
All of the time 4 most of the time 3 some of the time 2 a little of the time 
1 never 0 
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23.  During the past 2 weeks, how often have you been able to take part in your 
usual patterns of leisure or recreational activities? 
 
All of the time 4 most of the time 3 some of the time 2 a little of the time 
1 never 0 
 
 
24.  During the past 2 weeks, how much have you been troubled by the medical 
treatment of your health? 
 
Very much 0   much 1 somewhat 2  a little 3  not 
at all 4 
 
25.  To what extent have your personal relations with people close to you (family 
or friends) worsened because of your health? 
 
Very much 0  much 1 somewhat 2  a little 3  not 
at all 4 
 
 
26.  To what extent has your sexual life been impaired (harmed) because of your 
health? 
 
Very much 0  much 1 somewhat 2  a little 3  not 
at all 4 
 
 
27.  How often during the past 2 weeks have you been troubled by fluid or food 
coming up into your mouth (regurgitation)? 
 
All of the time 0 most of the time 1 some of the time 2 a little of the time 
3 never 4 
 
 
28.  How often during the past 2 weeks have you felt uncomfortable because of 
your slow speed of eating? 
 
All of the time 0 most of the time 1 some of the time 2 a little of the time 
3 never 4 
 
 
29.  How often during the past 2 weeks have you had trouble swallowing your 
food? 
 
All of the time 0 most of the time 1 some of the time 2 a little of the time 
3 never 4 
 
 
30.  How often during the past 2 weeks have you been troubled by urgent bowel 
movements? 
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All of the time 0 most of the time 1  some of the time 2 a little of the time 
3 never 4 
 
 
31.  How often during the past 2 weeks have you been troubled by diarrhea? 
 
All of the time 0 most of the time 1 some of the time 2 a little of the time 
3 never 4 
 
 
32.  How often during the past 2 weeks have you been troubled by constipation? 
 
All of the time 0 most of the time 1 some of the time 2 a little of the time 
3 never 4 
 
 
33.  How often during the past 2 weeks have you been troubled by nausea? 
 
All of the time 0 most of the time 1 some of the time 2 a little of the time 
3 never 4 
 
 
34.  How often during the past 2 weeks have you been troubled by blood in the 
stool? 
 
All of the time 0 most of the time 1 some of the time 2 a little of the time 
3 never 4 
 
 
35.  How often during the past 2 weeks have you been troubled by heartburn? 
 
All of the time  0 most of the time 1 some of the time 2 a little of the time 
3 never 4 
 
 
36.  How often during the past 2 weeks have you been troubled by uncontrolled 
stools? 
 
All of the time 0 most of the time 1 some of the time 2 a little of the time 
3 never 4 
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Appendix F - Randomization schedule:  With product coding and after 
unblinding 
ID Women Women Unblinded 
1 4H2 - 3W8  BA  Fiber-Control 
2 9J1 - 5E1  BA  Fiber-Control 
3 3W8 - 4H2  AB  Control-Fiber 
4 5E1 - 9J1  AB  Control-Fiber 
5 4H2 - 3W8  BA  Fiber-Control 
6 3W8 - 4H2  AB  Control-Fiber 
7 9J1 - 5E1  BA  Fiber-Control 
8 3W8 - 4H2  AB  Control-Fiber 
9 5E1 - 9J1  AB  Control-Fiber 
10 4H2 - 3W8  BA  Fiber-Control 
    ID Men Men Unblinded 
21  9J1 - 5E1  BA Fiber-Control 
22  3W8 - 4H2  AB Control-Fiber 
23  5E1 - 9J1  AB Control-Fiber 
24  4H2 - 3W8  BA Fiber-Control 
25  3W8 - 4H2  AB Control-Fiber 
26  9J1 - 5E1  BA Fiber-Control 
27  5E1 - 9J1  AB Control-Fiber 
28  4H2 - 3W8  BA Fiber-Control 
29  9J1 - 5E1  BA Fiber-Control 
30  3W8 - 4H2  AB Control-Fiber 
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Appendix G - Bristol Stool Chart 
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Appendix H - Flow Chart 
VISITS V0 V1 HOME V2 HOME V3 HOME V4 HOME V5
DAYS 0 1 1 to 14 14 (+/-2) 14 - 28 28 (+/-2) 28 - 56 56 (+/-2) 56 - 70 70 (+/-2)
PHASE Habitual 
Diet
Blinded 
treatment 1
WASHOUT Blinded 
treatment 2
MEASURES:
Informed consent X
Delivery of stool sample 
collection kits, diet records, 
radio opaque pellets and  
GI tolerance diaries/ 
instruments
X X X X
Diet records I---------I I---------I Day 42-56 I---------I X
Gastrointestinal tolerance I---------I I---------I Day 42-56 I---------I X
Stool sample collection Day 9-13 Fresh 
sample
Day 23-27 Fresh 
sample
Day 51-55 Fresh 
sample
Day 65-69 Fresh 
sample
Radio opaque pellets 
consumption
Day 8 Day 22 Day 50 Day 64
Gastrointestinal quality of 
life (TBD)
X X X X
Collection of diet records X X X X
Collection of tolerance 
instrument
X X X
Microbiota X X X X
Fecal Moisture X X X X
Stool weight X X X X
Transit time X X X X
Stool pH X X X X
Short chain fatty acids X X X X
Height X
Body weight X X X X X X
Bristol stool scale X X X X
Distribution of product for 
next phase
X  X
Compliance X X X X
Health History / Status X X X X X X
Concomitant Medication X X X X X X
AE / SAE Assessment X X X X X
Randomization / IP 
Assignment
X X
 
 
 
 
 
 
 
 
 
 
